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ABSTRACT 
 
Khambaty, Tasneem. Ph.D., Purdue University, August 2015. Depression Treatment and 
Diabetes Risk: A 9-Year Follow-Up Study of the IMPACT Trial. Major Professor: Jesse 
C. Stewart. 
 
Objectives: To examine the effect of a collaborative care program for late-life depression 
on risk of diabetes among depressed, older adults.  
Method: We conducted a 9-year follow-up study of 160 older, primary care patients with 
a depressive disorder but without diabetes enrolled at the Indiana sites of the Improving 
Mood-Promoting Access to Collaborative Treatment (IMPACT) trial.  
Results: Surprisingly, the rate of incident diabetes in the collaborative care group (22/80 
= 27.5%) was twice the rate observed in the usual care group (11/80 = 13.7%). Cox 
proportional hazards models adjusted for randomization status (HR = 1.94, p = .076), 
demographic factors (HR = 1.94, p = .075), and additionally for diabetes risk factors (HR 
= 1.73, p = .157) indicated that the risk of incident diabetes did not differ between the 
collaborative care and usual care groups with collaborative care patients remaining at a 
nonsignificant increased risk. 
Conclusions: Our novel findings suggest that depression may not be a casual risk factor 
for diabetes and that depression treatment may be insufficient to reduce the excess 
diabetes risk of depressed, older adults.
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CHAPTER 1 INTRODUCTION 
 
1.1 Overview 
Diabetes is a serious metabolic condition that is highly prevalent worldwide and 
has substantial consequences for individuals affected by it and for society. Depression is 
also highly prevalent and is the leading cause of disability worldwide (Pratt & Brody, 
2008). Considerable epidemiologic evidence indicates that depression is an independent 
risk factor for diabetes, with risk ratios similar to traditional diabetes risk factors (Pratt & 
Brody, 2008). There are also hypothesized behavioral and biological mechanisms that 
may underlie the depression-to-future-diabetes relationship (Bi et al., 2012; Centers for 
Disease Control and Prevention, 2011; Mozaffarian et al., 2009). Taken together, these 
findings suggest that depression may be a causal risk factor for diabetes. Unfortunately, 
due to the dearth of intervention studies involving depressed patients initially free of 
diabetes, it is unknown whether depression treatment prevents or delays the onset of 
diabetes. The proposed study began to address this critical gap in the literature by 
examining the effect of a collaborative care program for late-life depression on the risk of 
diabetes among older adults initially free of diabetes. To test the study hypotheses, the 
present study utilized data from the Improving Mood-Promoting Access to Collaborative 
Treatment (IMPACT) trial linked with electronic medical record data and 
Medicare/Medicaid data. 
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This paper begins with a summary of the significance, prevalence and incidence, 
pathophysiology, and risk factors of type 2 diabetes. Next, a brief introduction to 
depressive disorders is provided, followed by a review of the depression-diabetes 
literature, including both epidemiologic and intervention studies. Then, hypothesized 
mechanisms that may underlie the depression-to-future-diabetes relationship and the 
effect of depression treatment on incident diabetes are discussed. Next, the hypotheses 
and methods of the proposed study are presented, followed by the results obtained from 
conducting the proposed analyses. In the discussion section, a summary of findings, their 
fit with the existing literature, and potential interpretations are presented. Limitations of 
the present study are also discussed, which inform future directions for this research area, 
the ultimate goal of which is the development of strategies for preventing diabetes among 
depressed persons. 
 
1.2 Type 2 Diabetes – A Worldwide Epidemic 
Diabetes mellitus is a cluster of metabolic diseases usually characterized by 
deficiencies in insulin secretion, insulin action, or both, ultimately leading to increased 
glucose concentrations in the blood, known as hyperglycemia (American Diabetes 
Association, 2010). The two major types of diabetes – Type 1 or insulin dependent and 
Type 2 or non-insulin dependent – have differing, multifactorial etiologies (Sacks et al., 
2011). The unifying feature is that both diseases are characterized by the overproduction 
and underutilization of glucose (Sacks et al., 2011). Of the two types, type 2 diabetes is 
the most common in adults, accounting for 90-95% of all diagnosed cases (Centers for 
Disease Control and Prevention, 2011). Type 2 diabetes is also the primary focus of this 
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proposal. In the sections below, the term ‘type 2 diabetes’ will be used when referring 
specifically to this type of diabetes. In contrast, the term ‘diabetes’ will be used to refer to 
both type 1 or type 2 diabetes together as is commonly done in the literature. 
A diagnosis of type 2 diabetes is established when the presence of hyperglycemia 
can be identified (Sacks et al., 2011). In 1979, and again in 1997, a standardized 
definition for the diagnosis of diabetes was established by the World Health Organization 
(WHO) (Sacks et al., 2011). According to their definition, a diagnosis should be given 
when any one of the following criteria are met on two separate days: (1) a fasting glucose 
level ≥ 126 mg/dL (7.0 mmol/L), (2) a glucose level two hours after a meal ≥ 200 mg/dL 
(11.1 mmol/L), or (3) symptoms of diabetes and a casual (i.e., regardless of time of 
preceding meal) glucose level ≥ 200 mg/dL. Of note, the cut points used in the criteria 
above were also agreed upon by the International Diabetes Federation and the American 
Diabetes Association (Sacks et al., 2011). In 2009, these governing bodies proposed that 
glycosylated hemoglobin (HbA1c) levels ≥ 6.5% should also be used to diagnose type 2 
diabetes. HbA1c reflects the average blood glucose concentration over a period of 90-120 
days and is therefore considered a more stable estimate than a single fasting or non-
fasting glucose measurement (Sacks et al., 2011). 
 
1.2.1 Significance 
Diabetes is a chronic, debilitating condition that, within the past few decades, has 
become a global public health crisis with substantial costs to society (Go et al., 2013). 
Diabetes is associated with reduced functional status, an elevated risk of complications 
and other medical conditions, increased health care utilization and costs, and mortality 
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(Brown, Mangione, Saliba, & Sarkisian, 2003). First, patients with diabetes have reduced 
functional status and quality of life due to limited mobility, increased pain, and greater 
dependency on family and friends (American Diabetes Association, 2013; Centers for 
Disease Control and Prevention, 2011). Another example of reduced functional status 
particularly relevant to this proposal is the twofold increased risk of depression that is 
associated with diabetes (Centers for Disease Control and Prevention, 2011). Second, it is 
well known that diabetes affects several bodily systems. Poorly managed diabetes is the 
leading cause of kidney failure, lower-limb amputations, and blindness and can also lead 
to periodontal disease, neuropathy, coma, cerebrovascular disease, and coronary artery 
disease (Go et al., 2013). Furthermore, individuals with diabetes are more susceptible to 
other illnesses, such as pneumonia or influenza, and are more likely to have worse 
prognosis and to die from these illnesses than individuals without diabetes (Centers for 
Disease Control and Prevention, 2011). Third, diabetes and its complications increase 
health care utilization and costs. Roughly 15% of hospital discharges in 2009 in the U.S. 
had diabetes as a listed diagnosis (Go et al., 2013). In 2012, the total costs of diagnosed 
diabetes were estimated to be $245 billion, of which $176 billion were direct medical 
costs and $69 billion were indirect costs due to work loss, disability, and premature 
mortality (American Diabetes Association, 2013). Medical costs for patients with 
diabetes are also 2.3 times higher than for individuals without diabetes (Centers for 
Disease Control and Prevention, 2011). Lastly, diabetes is associated with increased 
mortality. Based on death certificates in 2007, diabetes was the seventh leading cause of  
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death in the U.S. (Centers for Disease Control and Prevention, 2011). In 2010, 6.8% of 
deaths worldwide and 15.7% of deaths in North American were attributable to diabetes 
(Centers for Disease Control and Prevention, 2011).  
 
1.2.2 Prevalence and Incidence 
Worldwide, the prevalence of diabetes is 6.6%, a rate that is expected to rise to 
7.8% by the year 2030 (International Diabetes Federation, 2009; Stuart & Baune, 2012). 
In the U.S., the prevalence of diabetes is 8.3%, which amounts to 25.8 million individuals 
(Centers for Disease Control and Prevention, 2011). Perhaps equally concerning is the 
fact that 87.3 million individuals are in the pre-diabetic stage and an additional 8.2 
million individuals have undiagnosed diabetes (Go et al., 2013). It is also important to 
note that adults ≥ 65 years have the highest prevalence (26.9%) of diabetes of any age 
group (Go et al., 2013). With the rate with which the diabetes epidemic is progressing, it 
is estimated that, in all age, sex, and race/ethnicity groups in the U.S., the total prevalence 
of diabetes will more than double from 2005 to 2050 (Centers for Disease Control and 
Prevention, 2011). Moreover, the incidence of diabetes has tripled in the last 20 years. 
While roughly 600,000 new diabetes cases were diagnosed in 1990, approximately 1.9 
million new cases were diagnosed in 2010 among American adults aged 18-79 years 
(Centers for Disease Control and Prevention, 2012). Taken together, the substantial 
physical and financial costs and high prevalence and incidence of diabetes underscore the 
urgent need for approaches to prevent diabetes (American Diabetes Association, 2013). 
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1.2.3 Pathophysiology 
Normal glucose metabolism is primarily regulated by the hormone insulin, 
produced by the beta-cells in the islet of Langerhans within the pancreas (Stumvoll, 
Goldstein, & van Haeften, 2005). The primary tissues that insulin targets are liver, fat, 
and muscle cells (Kahn, 2001b). A feedback loop consisting of the pancreas, liver, and 
peripheral tissues is responsible for glucose metabolism and glucose-insulin homeostasis 
(Kahn & Porte, 2003). Within this feedback loop, an interchange occurs between two 
fundamental processes that results in homeostasis: (1) insulin action – the ability of 
insulin to act on peripheral tissues to stimulate glucose metabolism and inhibit hepatic 
glucose output, and (2) insulin secretion – the ability of beta-cells in the pancreas to 
produce insulin to match glucose output (Stumvoll et al., 2005). An important property of 
this feedback loop is that normal pancreatic beta-cells can adapt to changes in insulin 
action or secretion; a decrease in insulin action can lead to a compensatory increase in 
insulin secretion or vice versa.  
In type 2 diabetes, defects occur in both insulin action and secretion (Kahn, 
2001a). Defects in insulin action that result in the decreased ability of insulin to act on 
peripheral tissues to stimulate glucose uptake is known as insulin resistance. Insulin 
resistance can occur due to several reasons, including defects at the insulin receptor, a 
decrease in receptor number, and defects at several of the post-receptor steps involved in 
insulin action (Kahn, 2001a). Once initiated, insulin resistance manifests in skeletal 
muscles as a reduction in insulin-mediated glucose uptake (Henry, 2003), in the liver as 
an inadequate suppression of hepatic glucose production, and in the vasculature as 
abnormal endothelial function and increased production of proinflammatory markers 
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(Haffner, 2003; Wheatcroft, Williams, Shah, & Kearney, 2003). The ultimate result of 
insulin resistance is hyperglycemia (Kahn, 2001a).  
While nearly 90% of all patients with type 2 diabetes exhibit insulin resistance, its 
presence alone is not sufficient for type 2 diabetes to develop (Zimmet, Alberti, & Shaw, 
2001); defects in insulin secretion as a result of impaired beta-cell function are also 
necessary (Kahn, 2001b). During the earlier stages of insulin resistance, the pancreas can 
compensate by increasing insulin secretion. As a result of this hyperinsulinemia, the body 
metabolizes glucose at normal rates and, therefore, glucose tolerance tests are often 
normal. This intermediate stage can last from months to years and is known as pre-
diabetes. (Boden & Shulman, 2002; Pratley, 2006). In the more advanced pre-diabetic 
stage, as insulin resistance becomes more severe, high levels of insulin secretion are 
unable to compensate for the hyperglycemia. As a result of chronically elevated insulin 
production, individuals become relatively insulin deficient because the size of the beta-
cells decreases to nearly 40-60% of what would be considered normal (Weir & Halban, 
2001). This decrease in beta-cell mass leads to impaired beta-cell responsiveness to 
increases in glucose levels to the extent that the body’s ability to compensate for changes 
in insulin resistance becomes absent altogether (Pratley, 2006). At this point, circulating 
glucose levels are chronically elevated and likely to be identified as such by glucose 
tolerance tests and fasting or non-fasting glucose tests, leading to a diagnosis of type 2 
diabetes (Pratley, 2006).  
 
8 
 
 
 
1.2.4 Risk Factors 
As with most chronic diseases, both modifiable and nonmodifiable factors are 
thought to play an etiological role in the development of type 2 diabetes. Modifiable 
factors include obesity, physical inactivity, poor diet, smoking, and alcohol consumption, 
all of which independently predict incident diabetes (Mozaffarian et al., 2009). Of these, 
obesity has received the greatest attention. In the Nurses’ Health Study, women with a 
body mass index (BMI) of  ≥ 35.0 were 38.8 times more likely to develop type 2 diabetes 
than women with a BMI of < 23.0 (Hu et al., 2001). Second, physical inactivity is 
positively related to the development of type 2 diabetes. Data from the U.S. National 
Health and Nutrition Examination Survey (NHANES) revealed that every two hours per 
day spent watching television was associated with a 14% increase in diabetes risk, while 
the same amount of time standing or walking was associated with a 12% reduction in risk 
(Hu, Li, Colditz, Willett, & Manson, 2003). A recent meta-analysis involving 175,938 
individuals and 6,428 incident type 2 diabetes cases confirmed this risk, finding that two 
hours of television per day increased the risk of type 2 diabetes by 20% (Grøntved & Hu, 
2011). Third, poor diet has been shown to contribute to the development of diabetes, 
independent of BMI (Bi et al., 2012; Hu et al., 2001). The Nurses’ Health Study found 
that a higher dietary glycemic load was associated with a 16% increased diabetes risk (Bi 
et al., 2012; Hu et al., 2001). Additionally, meta-analytic results indicated that a higher 
consumption of sugar-sweetened beverages was associated with a 26% increased risk of 
type 2 diabetes (Malik et al., 2010). Fourth, compared to nonsmokers, current smokers 
have a 45% increased risk of diabetes, a risk that increases in a dose-response fashion 
with the number of cigarettes smoked (Ainsworth et al., 1993). Lastly, the relationship 
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between alcohol use and type 2 diabetes exhibits a U-shape, with moderate drinkers at a 
30-40% decreased risk than abstainers and heavy drinkers (Koppes, Dekker, Hendriks, 
Bouter, & Heine, 2005). To put these individual risk factors in perspective, data from the 
Cardiovascular Health Study found that individuals whose physical activity level and 
dietary, smoking, and alcohol habits were all in the low-risk group had an 82% lower 
incidence of type 2 diabetes than all other participants. Absence of obesity lead to a 
further decrease in risk of disease incidence to 89% (Mozaffarian et al., 2009).  
Nonmodifiable factors implicated in the development of type 2 diabetes are 
demographic factors, hypertension, and genetic factors. Demographic risk factors are 
older age and race/ethnicity (Centers for Disease Control and Prevention, 2011). Studies 
show that African Americans, Hispanic/Latino Americans, American Indians, and some 
Asian Americans, Native Hawaiians, and Pacific Islanders are groups at increased risk for 
type 2 diabetes compared to Caucasian Americans (Centers for Disease Control and 
Prevention, 2011). Hypertension is considered a risk factor for prediabetes according to 
the American Association of Clinical Endocrinologists guidelines (Handelsman et al., 
2011), with hypertensive persons thought to be 2.5 times as likely to develop prediabetes 
and type 2 diabetes than persons with normal blood pressure (Gress, Nieto, Shahar, 
Wofford, & Brancati, 2000). Moreover, beta-blockers commonly used in the treatment of 
hypertension appear to increase the risk of type 2 diabetes by 28% (Elliott & Meyer, 
2007; Gress et al., 2000). Genetic factors for type 2 diabetes have been a subject of 
increasing interest in recent years, particularly since the advent of genome-wide 
association studies (GWAS) (Bi et al., 2012). Much progress has been made in 
identifying diabetes susceptibility genes, with 38 genetic loci currently confirmed to be 
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associated with type 2 diabetes by GWAS studies (Bi et al., 2012). Most of the identified 
diabetes susceptibility genes are thought to affect beta-cell function instead of insulin 
resistance (Voight et al., 2010). 
 
1.3 Depression as a Potential Risk Factor for Diabetes 
In the mid-1980’s, researchers began to examine the potential role of 
psychological factors in the development and progression of type 2 diabetes, given some 
indication from clinical settings that psychological factors, particularly depressive 
disorders, were more prevalent among individuals with versus without diabetes (Lloyd et 
al., 2010). In the sections below, the definition, assessment, and prevalence of depressive 
disorders is briefly reviewed. Then the depression-diabetes literature, including both 
epidemiologic and intervention studies is summarized. Lastly, the hypothesized 
mechanisms that may underlie the depression-to-future-diabetes association and the 
effect of depression treatment on incident diabetes are discussed. 
 
1.4 Depressive Disorders 
Depressive disorders are highly debilitating conditions that affects both an 
individual’s mental and physical health and accounts for more disability than any other 
disorder worldwide (Pratt & Brody, 2008). These disorders are associated with decreases 
in quality of life, impairment in social and occupational functioning, and increases in 
health care costs (Pratt & Brody, 2008). Two types of depressive disorders are major 
depressive disorder (MDD)  and dysthymic disorder (American Psychiatric Association, 
2000; Fava & Kendler, 2000). MDD consists of the following four symptom clusters: 
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affective symptoms (depressed mood and anhedonia), cognitive symptoms (inappropriate 
guilt, poor concentration, indecisiveness, worthlessness, and recurrent thoughts of death 
or suicide), behavioral symptoms (psychomotor retardation or agitation), and somatic 
symptoms (weight loss or gain, sleep disturbances, and fatigue) (Fava & Kendler, 2000). 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR; 
American Psychiatric Association, 2000), five or more of these symptoms, including 
depressed mood or anhedonia, must last for at least two weeks for MDD to be diagnosed. 
Moreover, these symptoms must be the source of significant distress and impairment in 
one’s daily functioning and should not be accounted for by substance use or bereavement 
(American Psychiatric Association, 2000). Dysthymic disorder is a milder, although more 
chronic, form of depression in which two or more of the aforementioned symptoms in 
addition to depressed mood must be present for most of the day for at least 2 years 
(American Psychiatric Association, 2000). 
MDD and dysthymia are diagnosed through structured diagnostic interviews, but 
they are also commonly assessed using standardized self-report scales. The gold standard 
diagnostic interview for depression is the Structured Clinical Interview for DSM-IV 
(SCID; First, Spitzer, Gibbon, & Williams, 2002). The SCID is a semi-structured 
interview utilized commonly in research settings, which offers psychiatric diagnoses 
according to DSM-IV criteria by systematically inquiring about the presence or absence 
of particular symptoms (First et al., 2002). Self-report scales such as the Patient Health 
Questionnaire-9 (PHQ-9) or the Beck Depression Inventory (BDI) assess depressive  
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symptom severity. Generally, high scores on these scales are strongly correlated with the 
presence of depressive disorders (Goldston & Baillie, 2008; Williams Jr, Pignone, 
Ramirez, & Perez Stellato, 2002).  
Worldwide, depressive disorders are responsible for 4.8% of the total burden of 
disease, with figures increasing to 5.1% and 8.2% in middle and high-income countries 
respectively (Mathers, Fat, & Boerma, 2008). Moreover, by the year 2030, depressive 
disorders are thought to become the leading contributor to morbidity (Mathers et al., 
2008). MDD is currently the most common of the psychiatric disorders and, among 
“first-world” countries, the most common of all biomedical disorders (Fava & Kendler, 
2000). In the U.S., the lifetime prevalence of MDD is approximately 17% and a 12-
month prevalence is 7% (Fava & Kendler, 2000; Kessler, Chiu, Demler, & Walters, 
2005). Moreover, data collected in 2005-2006 found that in any 2-week period, 5.4% of 
Americans aged ≥ 12 years experience clinical depression, a rate that is highest among 
women, and individuals aged 40-59 years (Pratt & Brody, 2008). With regard to 
dysthymic disorder, the National Comorbidity Survey Replication reported a lifetime 
prevalence of 6.4%, and a 12-month prevalence of 1.5% (Kessler et al., 2005).   
 
1.5 Review of the Depression-Diabetes Literature 
1.5.1 Epidemiologic Studies 
Evidence from early epidemiologic investigations indicated that the prevalence of 
MDD is higher among individuals with diabetes versus those without this condition 
(Anderson, Freedland, Clouse, & Lustman, 2001; Lustman, Penckofer, & Clouse, 2007; 
Talbot & Nouwen, 2000). Systematic reviews have since confirmed that the prevalence 
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of MDD in patients with diabetes is up to 30%, nearly twofold higher than in patients 
with other medical illnesses (Ali, Stone, Peters, Davies, & Khunti, 2006; Anderson et al., 
2001). While several hypotheses have been posited to explain this high prevalence, the 
two dominant hypotheses are: (1) depression results from the psychosocial demands 
associated with the diagnosis and treatment of diabetes, sometimes referred to as the 
psychological burden hypothesis (Talbot & Nouwen, 2000), and (2) depression is a direct 
consequence of the pathophysiology or treatment of diabetes, also referred to as a mood 
disorder due to a medical condition (Talbot & Nouwen, 2000). In 2000, Talbot and 
Nouwen (2000) conducted a qualitative review of the diabetes-depression literature to 
gauge the degree of empirical support for these two hypotheses. The researchers included 
all data published before May 2000 and surprisingly found little evidence to support 
either hypothesis. Instead, the authors reported that in the majority of prospective studies 
reviewed, depressive symptomology preceded the onset of type 2 diabetes by several 
years, which led them to conclude that there is more evidence for depression as a 
candidate risk factor for type 2 diabetes than a consequence.  
The earliest study to document that MDD predicted the development of type 2 
diabetes was conducted by Eaton and colleagues (1996). These researchers examined 
data from 1,715 individuals who were initially free of type 2 diabetes from the 
Epidemiologic Catchment Area program survey. Participants were followed over 13 
years, during which 89 (5.2%) participants developed type 2 diabetes. Logistic models, 
adjusted for demographic factors and BMI, revealed that MDD predicted the onset of 
type 2 diabetes. Specifically, individuals with MDD had a more than twofold increased 
risk of developing type 2 diabetes than nondepressed individuals. This population-based 
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longitudinal study stimulated future research on the depression-incident diabetes 
association (Lustman, Penckofer, et al., 2007). In a large community sample of 4,803 
adults aged 55 years and older, Campayo et al. (2010) further determined that – even 
after adjusting for sociodemographic factors, diabetes risk factors, and antidepressant 
medication use – subclinical or minor depression (OR = 1.66), persistent depression (OR 
= 2.09), and untreated depression (OR = 1.83) were all associated with greater risk of 
incident diabetes (either type 1 or type 2). 
Utilizing data from the  First National Health and Nutrition Examination 
Epidemiologic Follow-up Study, Carnethon et al. (2003) examined whether the 
prospective association between depression and diabetes (type 1 or type 2) is mediated by 
established risk factors for diabetes. Over 16 years, 369 (6%) of the 6,190 adults 
developed diabetes. The risk of incident diabetes was two times higher among adults 
depressed at baseline versus those who were not depressed, although only among 
individuals who had less than a high school education. Moreover, the association between 
depressive symptoms and incident diabetes was strongest among women. Lastly, 31% of 
the observed association was explained by BMI, while another 6% was explained by 
lifestyle behaviors of smoking, alcohol use, and physical inactivity (Carnethon et al., 
2003). In a study of 5,201 participants from the Multi-Ethnic Study of Atherosclerosis, 
Golden et al. (2008) repeatedly measured depressive symptoms and fasting blood glucose 
over three years. Adjusting for sociodemographic, metabolic, and inflammatory markers, 
the researchers found that the risk of incident type 2 diabetes was 1.10 times higher for 
each 5 unit increase in the CES-D scale, suggesting a graded association.  
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The findings of the aforementioned studies have been further replicated in 
samples of younger (Brown, Majumdar, Newman, & Johnson, 2005) and older adults 
(Carnethon et al., 2007), samples of men (Kawakami, Takatsuka, Shimizu, & Ishibashi, 
1999) and women (Arroyo et al., 2004; Everson-Rose et al., 2004), and in studies 
utilizing self-report depression assessments (Kawakami et al., 1999) and diagnostic 
interviews (Eaton, Armenian, Gallo, Pratt, & Ford, 1996; Mezuk, Eaton, Albrecht, & 
Golden, 2008). Furthermore, a recent meta-analysis confirms the elevated diabetes risk 
associated with depression and provides an overall estimate of the magnitude of this 
prospective association. Mezuk et al. (2008) compiled 20 longitudinal studies to examine 
(1) diabetes as a predictor of future depression and (2) depression as predictor of future 
diabetes. The analysis of seven studies exploring the first direction revealed that diabetes 
was associated with a modest 15% increase in risk of developing depression. The 
analyses of 13 studies exploring the second direction revealed that depression was 
associated with a 60% increase in risk of developing type 2 diabetes. Demographic 
factors were not found to be moderators of this relationship. This meta-analysis suggests 
that the depression-diabetes relationship is bidirectional, although the magnitude of the 
depression-to-future-diabetes relationship appears to be stronger than that of the diabetes 
to depression relationship. To summarize, results of epidemiologic studies suggest that 
depression is an independent risk factor of type 2 diabetes. Importantly, the risk conferred 
by depression rivals in magnitude with other known risk factors for the disease, including 
obesity, smoking, and physical inactivity (Golden et al., 2008; Mezuk et al., 2008). 
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1.5.2 Treatment Studies 
To determine whether depression is a causal risk factor for type 2 diabetes, 
depression intervention studies are needed. Ideally, these studies would involve adults 
with depression but not diabetes at baseline. However, there are only a few studies of this 
type in the literature. Far more intervention studies involve patients with comorbid 
depression and type 2 diabetes. The aim of these studies has been to determine whether 
treating depression can improve diabetes prognosis, most commonly indicated by 
glycemic control (i.e., HbA1c levels)  (Katon & Felz‐Cornelis, 2010). These studies, 
although not ideal, can also provide information relevant to this proposal. For instance, if 
depression treatment among patients with diabetes has a beneficial influence on diabetes 
markers, these studies would provide indirect support for the notion that depression 
treatment delivered to depressed patients at risk for diabetes may also influence 
subclinical diabetes markers or underlying mechanisms (e.g., insulin resistance) and 
delay or prevent diabetes onset. In the following section, intervention studies involving 
individuals without and with diabetes at baseline are reviewed.  
 
1.5.2.1 Individuals without Baseline Diabetes 
Although not a randomized controlled trial (RCT), a small proof-of-concept study 
provides initial evidence of a positive effect of depression treatment on subclinical 
diabetes outcomes. Okamura et al. (2000) compared 20 nondiabetic patients with 
depression before depression treatment to 13 age-, sex-, and BMI-matched nondiabetic 
adults without depression. Depressed patients were found to have lower insulin 
sensitivity than their nondepressed counterparts. Then, during a treatment phase, 
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depressed patients were given tricyclic or tetracyclic antidepressants and asked to 
maintain a 1,800–2,200 kcal per day diet and avoid aerobic exercise. Okamura et al. 
compared their pre- and post-treatment oral glucose tolerance tests and found that there 
was significant improvement in insulin sensitivity after treatment, with no concurrent 
changes in the BMI or fasting blood glucose. These results suggest that depression 
treatment may decrease the risk of diabetes by improving insulin sensitivity. 
In a double-blind RCT (Weber-Hamann, Gilles, Lederbogen, Heuser, & 
Deuschle, 2006), 80 inpatients with MDD but not diabetes were randomized to either 
paroxetine (a selective serotonin reuptake inhibitor; SSRI) or amitriptyline (a tricyclic 
antidepressant). Over a 5-week period, insulin sensitivity improved only among patients 
who achieved depression remission following treatment with either antidepressant. 
Improvement in insulin sensitivity was again not accounted for by changes in BMI. A 
subsequent investigation by the same authors found similar results. In that study, 51 
inpatients with MDD but not diabetes were given either mirtazapine (a tetracyclic 
antidepressant) or venlafaxine (a dual noradrenergic and serotonergic reuptake inhibitor) 
(Weber-Hamann et al., 2008). Over the 4-week treatment period, depression remission 
was associated with a significant improvement in insulin sensitivity, with a nonsignificant 
trend towards a more pronounced effect of mirtazapine than venlafaxine. However, there 
was no effect of antidepressants on insulin sensitivity in the absence of depression 
remission, suggesting that the observed effect was depression dependent and not due to 
the direct physiologic effects of the medications. 
In contrast, another study reported a null effect of depression treatment on insulin 
sensitivity. Kauffman et al. (2005) enrolled 14 depressed and 18 nondepressed women 
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aged 18-45 years. All depressed women were given citalopram (a SSRI), and the 
nondepressed women were randomly assigned to citalopram or no treatment. Before 
treatment, no differences in insulin sensitivity were found between depressed and 
nondepressed women. After 8 weeks of treatment, no differences were detected in oral 
glucose tolerance tests between the three groups, indicating no improvement in insulin 
sensitivity. The fact that the depressed women were euglycemic at baseline may partly 
explain the lack of group differences, as it is possible that there was limited margin for 
improvement in insulin sensitivity. 
To summarize, there are few studies that evaluate the effect of depression 
treatment on diabetes-related outcomes among individuals initially free of diabetes. The 
available data suggests that depression treatment may improve insulin sensitivity and, 
therefore, provides preliminary support for the notion that depression treatment may 
prevent or delay the onset of type 2 diabetes. Of note, the effect on insulin sensitivity may 
be depression dependent, as remission appears to be required. However, given that the 
existing trials are small and lacking in methodological rigor (e.g., lack of randomization 
and absence of a control group), there is a need for well-designed intervention studies 
evaluating the effect of depression treatment on incident diabetes among depressed 
patients without diabetes at baseline.  
 
1.5.2.2 Individuals with Baseline Diabetes 
Among individuals with comorbid depression and diabetes, research has primarily 
examined whether depression interventions reduce depressive symptoms and only 
secondarily examined whether these interventions also improve diabetes outcomes. 
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Because the secondary question is more relevant to this proposal, I review the existing 
studies utilizing pharmacological, psychological, or collaborative care interventions 
below, with a focus on diabetes outcomes. 
 
1.5.2.2.1 Pharmacologic Interventions 
Lustman et al. (1997) conducted one of the earliest trials in this area, enrolling 68 
patients with type 1 or type 2 diabetes, of which 28 individuals also had MDD.  
Participants were randomized to an 8-week regimen of either nortriptyline (a tricyclic 
antidepressant) or placebo. Analyses revealed that, compared to placebo, nortriptyline 
significantly improved depression symptoms but not HbA1c levels. In subsequent path 
analyses, the authors found that while the direct effect of nortriptyline was to worsen 
HbA1c levels, the effect of depression remission was to improve glycemic control. Given 
the detrimental effects of tricyclic antidepressants, in a subsequent study, the same 
researchers investigated the effects of fluoxetine (a SSRI) on glycemic control among 60 
diabetic patients (type 1 or type 2) with MDD (Lustman, Freedland, Griffith, & Clouse, 
2000). After an 8-week treatment period, participants given antidepressant medication 
compared to placebo showed a trend toward greater reduction in HbA1c levels. Of note, 
neither changes in weight loss nor depression were responsible for this effect. Although 
providing only modest evidence that pharmacologic depression treatment influences 
diabetes outcomes, these studies suggest that the effect of antidepressant medications on 
diabetes markers was not uniform (Lustman, Williams, Sayuk, Nix, & Clouse, 2007). 
Specifically, it appeared that while older tricyclic antidepressants had hyperglycemic 
effects, newer SSRIs had hypoglycemic or null effects. 
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Longer term studies that examine the efficacy of continuing antidepressant 
medication to prevent depression relapse more clearly demonstrate that improvement in 
depression leads to better glycemic control. For instance, in a double-blind RCT, 351 
patients with comorbid MDD and type 2 diabetes were given sertraline during a 16-week 
treatment phase (Lustman et al., 2006). After this phase, the 152 patients who recovered 
from depression continued to a maintenance phase in which they were randomized to 
treatment with sertraline at a remission dose or placebo for the next 52 weeks or until 
depression recurred (Lustman et al., 2006). HbA1c levels were reduced not only in the 
treatment phase, but also the maintenance phase compared to baseline, indicating a 
positive effect of depression treatment on glycemic control. A subsequent smaller study 
confirmed these findings and further attributed improvements in glycemic control directly 
to depression improvement (Lustman, Penckofer, et al., 2007). These longer term studies 
lend further support to the notion that depression remission may be required for there to 
be salutary effects on diabetes markers.  
 
1.5.2.2.2 Psychological Interventions 
Several studies have examined the effects of psychological interventions on 
diabetes outcomes, with the main advantage of removing any potential for direct 
medication effects. As an example, one study assessed the influence of  cognitive 
behavioral therapy (CBT) on depression and HbA1c levels over a 10-week treatment 
phase and an additional 6-month follow-up period (Lustman, Griffith, Freedland, Kissel, 
& Clouse, 1998). The study involved a comparison of an individual CBT program plus 
diabetes education to diabetes education alone. While no statistically significant 
21 
 
 
 
difference was observed in HbA1c levels between groups at post-treatment, lower HbA1c 
levels were observed in the CBT group at the 6-month follow-up. Regarding the lag in 
glycemic control improvement, the authors reasoned that, because HbA1c is a "weighted" 
measure that averages blood glucose levels over the preceding 90-120 days, the 6-month 
HbA1c value, but not the post-treatment value measured directly after the treatment period 
would reflect improvement (Lustman et al., 1998). Although another study utilizing a 
nurse-administered minimal CBT program (4 sessions) corroborated the above findings 
(Lamers, Jonkers, Bosma, Knottnerus, & van Eijk, 2011), other investigations using web-
based CBT (van Bastelaar, Pouwer, Cuijpers, Riper, & Snoek, 2011) or telephone CBT 
(Piette et al., 2011) demonstrated null results.  
 
1.5.2.2.3 Collaborative Care Interventions 
A collaborative care intervention is a health services model designed to deliver 
evidence-based depression treatment in primary care settings (Katon & Felz‐Cornelis, 
2010; Van der Feltz-Cornelis et al., 2010). A collaborative care intervention generally 
consists of the following components: (1) a team approach to care in which depression 
specialists work with primary care physicians to deliver depression care, (2) the use of 
brief assessments to monitor symptoms, and (3) stepped care approaches, which involve 
complementing or changing initial pharmacologic or psychological treatment based on 
the persistence of symptoms (Katon & Felz‐Cornelis, 2010; Katon & Seelig, 2008). At 
least four collaborative care interventions trials have been conducted among depressed 
patients with diabetes (Ell et al., 2010; Katon & Felz‐Cornelis, 2010; Katon et al., 2004; 
Williams, Katon, et al., 2004). One such trial conducted by Williams et al. (2004) is a 
22 
 
 
 
good example, as they examined data that will also be utilized in the present study. The 
researchers conducted a preplanned subgroup analysis involving the 417 participants of 
the IMPACT trial who had diabetes at baseline. Along with the 1,384 IMPACT 
participants without diabetes, these individuals were randomized to the IMPACT 
intervention, a 12-month collaborative care intervention for late-life depression, or to 
usual care. Patients in the intervention group received a stepped care program consisting 
of antidepressant medication and/or problem solving therapy, while usual care patients 
received notification, along with their primary care physician, that they met criteria for a 
depressive disorder and were encouraged to follow-up regarding their symptoms. 
Analyses revealed significant decreases in depressive symptoms in the collaborative care 
versus usual care group, but no difference in HbA1c levels. Importantly, the three other 
collaborative care trials similarly failed to detect an effect of collaborative depression 
care on glycemic control. One explanation for these null results offered by Williams et al. 
(2004) was that, because the patients exhibited good glycemic control at baseline, there 
may have been a limited margin to detect further improvements. In addition, a lack of 
recovery from depression in the intervention arm may also be responsible for the null 
effects on diabetes outcomes. For example, in the Pathways study (Katon et al., 2004), 
roughly 45% of intervention patients had significant depressive symptoms at the end of 
the treatment period. Lastly, if improvement in glycemic control lags behind 
improvement in depressive symptoms, assessment of glycemic control immediately after 
treatment may have been premature, yielding no differences.   
To date, one meta-analysis has aggregated data from existing clinical trials. Van 
der Feltz-Cornelis et al. (2010) identified 14 trials, of which six utilized pharmacologic 
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interventions, five utilized psychological interventions, and three utilized collaborative 
care interventions. The standardized effect sizes of the pharmacologic trials, of which all 
but one evaluated the effect of SSRIs, was moderate for depressive symptoms (d = -0.61) 
and small for glycemic control (d = -0.38). The standardized effect size of the 
psychological interventions was moderate-to-large for both depressive symptoms (d = -
0.64) and glycemic control (d = -0.48). With regard to the collaborative care trials (Ell et 
al., 2010; Williams, Katon, et al., 2004), the authors only provided a pooled effect size 
for a combined outcome of depression and glycemic control (d = -0.29) (Katon & Felz‐
Cornelis, 2010). However, given that none of these trials reported significant 
improvement in glycemic control, this pooled effect size likely reflects improvement only 
in depressive symptoms in the collaborative care arm compared to the usual care arm. 
 In summary of intervention studies involving patients with comorbid depression 
and diabetes, some but not all studies indicate that depression treatment improves both 
depression and diabetes outcomes. These studies further suggest that depression 
remission may be a necessary component if improvement is to occur in diabetes 
outcomes. However, in terms of determining whether depression may be a potentially 
causal risk factor for diabetes, these studies are not ideal due to their choice of 
participants (patients with diabetes at baseline). Nonetheless, these studies provide 
indirect support for the notion that depression treatment delivered to depressed patients at 
risk for diabetes may also influence subclinical diabetes markers or underlying 
mechanisms (e.g., insulin resistance) and delay or prevent diabetes onset.  
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1.6 Potential Mechanisms Underlying the Depression-Diabetes Relationship 
Several behavioral and biological mechanisms have been proposed to explain the 
prospective association between depression and diabetes (see Figure 1), although they 
remain poorly understood. It is known, however, that these candidate mechanisms are 
interrelated and discussion of one often includes reference to others (Stuart & Baune, 
2012). These mechanisms are reviewed in the next two sections. Furthermore, several of 
the same mechanisms are also hypothesized to mediate the effect of depression treatment 
on diabetes outcomes. The third section below discusses the available mechanistic 
findings from intervention studies. 
 
1.6.1 Behavioral Mechanisms 
Depressed patients exhibit poor health behaviors that can increase diabetes risk 
(Golden et al., 2008; Ismail, 2010). Research shows that depressed patients are more 
likely to have deleterious dietary and physical activity behaviors (Golden et al., 2008; 
Ismail, 2010; Marcus, Wing, Guare, Blair, & Jawad, 1992; Roose et al., 2006), resulting 
in greater caloric intake (Golden, 2007; Golden et al., 2004) and a sedentary lifestyle 
(Carnethon et al., 2007; Carnethon et al., 2003; Everson-Rose et al., 2004). Depressed 
patients are also more likely to be noncompliant with medication, exercise, and diet 
recommendations, which can prolong depressive symptoms and further promote 
overeating and a sedentary behavior (Ismail, 2010). All of these factors have been shown 
to contribute to obesity, which is a strong risk factor for type 2 diabetes (Ismail, 2010). 
Moreover, physical inactivity decreases insulin sensitivity and is considered a risk factor 
for insulin resistance independent of obesity (Wagner, Allen, Swalley, Melkus, & 
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Whittemore, 2009; Weber-Hamann et al., 2006). Furthermore, depressed patients are 
twice as likely to engage in smoking as non-depressed patients (Lin et al., 2004; Strine et 
al., 2008). In turn, smoking is a risk factor for diabetes via its association with central 
obesity, increased inflammation, and beta-cell function damage (Canoy et al., 2005; 
Chang, 2012; Morrow et al., 1995; Spector & Blake). 
 
1.6.2 Biological Mechanisms 
Depression may activate several interrelated biological systems that can result in 
the development of insulin resistance and type 2 diabetes. These systems include the 
hypothalamic-pituitary-adrenal (HPA) axis, the sympathetic nervous system, and the 
innate immune system (Ismail, 2010). Depression is associated with HPA axis 
hyperactivation, as evidenced by elevated free, unbound cortisol levels in the plasma, 
increased 24-hour urinary free cortisol secretion, and elevated corticotropin releasing 
hormone levels in cerebrospinal fluid among depressed patients compared to controls 
(Fountoulakis, Gonda, Rihmer, Fokas, & Iacovides, 2008; Ismail, 2010; Otte et al., 2004; 
Rustad, Musselman, & Nemeroff, 2011; Stewart, 2008; Vreeburg et al., 2009). While a 
temporary HPA hyperactivation initiates a cascade of responses ending with the release 
of cortisol into the blood to help address the stressor, chronically high cortisol levels (a) 
activate the body’s innate inflammatory response, (b) contribute to increased visceral fat 
and central adiposity, and (c) activate the sympathetic nervous system resulting in the 
further increase in inflammatory markers and the release of catecholamines epinephrine 
and norepinephrine (Ismail, 2010; Roose et al., 2006). The collective metabolic effect of 
increased cortisol levels is to stimulate glucose production, decrease insulin secretion 
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from beta-cells, and decrease insulin sensitivity, all of which are implicated in the 
pathogenesis of type 2 diabetes (Knol et al., 2006; Rustad et al., 2011; Stewart, 2008). 
The finding that depression is associated with immune system activation and 
increased synthesis of inflammatory markers, including acute phase proteins (e.g., C-
reactive protein) and proinflammatory cytokines (e.g., interleukin-6), has been found in 
both human and animal studies (Howren, Lamkin, & Suls, 2009; Nouwen et al., 2011). 
Additionally, the presence of obesity among depressed patients also leads to 
proinflammatory cytokine production from adipocytes and macrophages accumulated in 
fat tissue (Ismail, 2010). These inflammatory markers inhibit insulin’s intracellular 
signaling cascade, ultimately decreasing insulin sensitivity and contributing to the 
development of type 2 diabetes (Ismail, 2010; Stuart & Baune, 2012). Moreover, a 
proinflammatory state within the liver and skeletal muscle, which are the primary tissues 
responsible for the maintenance of glucose homeostasis in response to insulin, can lead to 
insulin resistance within these tissues and result in pancreatic beta-cell apoptosis that is 
characteristic of type 2 diabetes (Stuart & Baune, 2012). 
 
1.6.3 Treatment Mechanisms 
Some but not all intervention studies demonstrate that depression treatment 
improves insulin sensitivity among depressed patients without diabetes and glycemic 
control among depressed patients with diabetes. With regard to the positive effect of 
depression treatment on diabetes outcomes, researchers hypothesize that the treatment-
related reductions in depressive symptoms may result in improvement in several of the 
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behavioral and biological mediators depicted in Figure 1, which in turn could delay or 
prevent the onset of insulin resistance and type 2 diabetes. 
A number of intervention studies have also explored candidate mechanisms 
underlying observed treatment effects. In terms of behavioral mediators, body 
weight/composition has thus far received the most attention. On the one hand, Lustman et 
al. (2007) found that improvements in glycemic control over the treatment period were 
due to improvement in both body composition and depressive symptoms. On the other 
hand, other studies indicate that the effect of depression treatment on insulin sensitivity 
among nondiabetic individuals and on glycemic control among diabetic individuals was 
unrelated to changes in BMI or body composition (Lustman et al., 2000; Lustman et al., 
1997; Okamura et al., 2000; Weber-Hamann et al., 2006; Weber-Hamann et al., 2008). A 
second behavioral mediator examined in diabetes trials has been diabetes self-care. The 
path analysis conducted by Lustman et al. (1997) and the maintenance trial by the same 
researchers (Lustman et al., 2007) found that the effect of antidepressant medication on 
glycemic control was not due to better compliance with self-monitoring of blood glucose 
or other types of diabetes self-care. Other behavioral mediators, such as physical activity 
could also underlie the effect of depression treatment on incident diabetes, but have not 
been assessed in treatment trials thus far. In terms of biological mediators, studies 
involving individuals initially free of diabetes (Okamura et al., 2000; Weber-Hamann et 
al., 2006; Weber-Hamann et al., 2008) suggest that depression treatment may delay or 
prevent type 2 diabetes by improving insulin sensitivity. Weber-Hamann et al. (2006) 
also found a decline in cortisol levels after depression treatment, which could lead to 
improved insulin sensitivity. However, decreased cortisol levels were found only among 
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individuals who received one type of antidepressant medication (amitriptyline) but not 
another (paroxetine). Other biological mediators, such as decreased systemic 
inflammation or sympathetic nervous system activation could also result in decreased risk 
of type 2 diabetes, but have not been assessed in treatment trials thus far. In short, this 
research remains incomplete and is far from conclusive. Furthermore, very few studies 
have conducted tests of statistical mediation. Such tests in future investigations may 
provide valuable data and eventually allow for the targeting of these specific mechanisms 
to prevent type 2 diabetes among depressed individuals.  
 
1.7 The Present Study 
Beginning with the earliest study by Eaton et al. (1996), data from prospective 
epidemiologic studies provide convincing evidence that depression is an independent risk 
factor for type 2 diabetes. However, intervention studies involving depressed adults 
initially free of diabetes seeking to test whether depression is a causal risk factor for type 
2 diabetes are scarce and contain important methodological flaws. The few available 
studies provide preliminary evidence that depression treatment improves insulin 
sensitivity and suggest that depression remission may be required for there to be any 
influence on diabetes markers. More intervention studies have been conducted among 
depressed patients with diabetes, although these types of studies cannot address whether 
depression plays a role in the development type 2 diabetes. Nonetheless, this indirect 
evidence suggests that depression treatment may be effective in addressing the 
hyperglycemia present in diabetic patients, although not unequivocally. To summarize,  
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given the lack of well-designed intervention trials involving depressed patients without 
diabetes, it remains unknown whether evidence-based depression treatment prevents or 
delays the onset of type 2 diabetes. 
The present study began to address this critical gap in the literature by examining 
the effect of a collaborative care program for late-life depression on the risk of diabetes 
among older adults initially free of diabetes. The specific hypotheses of this study were: 
Hypothesis #1: Depressed patients randomized to collaborative depression care 
have a lower incidence of type 2 diabetes than depressed patients randomized to usual 
care. 
Hypothesis #2: Change in depressive symptoms during the trial mediates the 
hypothesized beneficial effect of collaborative depression care on incident diabetes.  
Hypothesis #3: Antidepressant treatment received during the trial mediates the 
hypothesized beneficial effect of collaborative depression care on incident diabetes.  
Hypothesis #4: Psychotherapy received during the trial mediates the hypothesized 
beneficial effect of collaborative depression care on incident diabetes.  
To test these hypotheses, a 9-year follow-up study of the Improving Mood-
Promoting Access to Collaborative Treatment (IMPACT) trial was conducted. The 
IMPACT trial was a multisite RCT examining the effectiveness of a collaborative care 
program for late-life depression. Briefly, 1,801 older, depressed primary care patients 
were randomly assigned to the IMPACT intervention, a 12-month collaborative care 
program that included antidepressants and/or psychotherapy, or to usual care. The 
IMPACT intervention was found to be more effective than usual care in reducing 
depressive symptoms; 45% of the IMPACT patients, versus 19% of the usual care 
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patients, achieved a 50% reduction in SCL-20 score at 12-month follow-up (Unützer, 
Katon, et al., 2002). The present study utilized data from the 235 participants enrolled 
from the Indiana sites of the IMPACT trial, linked with electronic medical record data 
and Medicare/Medicaid data to provide the 9 years of follow-up. This combination of 
data is unique and addresses some of the limitations of previous studies, including small 
sample sizes and the absence of a control group. Demonstrating that depression treatment 
reduces the risk of type 2 diabetes would identify depression as a modifiable risk factor 
for diabetes and suggest that depression treatment should be included in diabetes 
prevention efforts.
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CHAPTER 2 METHOD 
 
2.1 Participants 
The IMPACT trial was conducted from 1999 to 2002 at seven study sites across 
five states (Unützer, Katon, et al., 2002). Participants were from 18 primary care clinics 
representing 8 diverse health care organizations. The study protocol was reviewed and 
approved by institutional review boards at all sites as well as the study coordinating 
center. All participants provided written informed consent. 
To recruit a sample from the target population of depressed, older adults, a two-
pronged strategy was used (Unützer, Katon, et al., 2002). The first strategy was to 
systematically screen (either in person or over the telephone) English speaking, older 
adults attending the participating primary care clinics using a two-item depression 
screener adapted from the PRIME-MD (Spitzer et al., 1994). The second strategy was to 
distribute promotions for the study at the participating clinics and accept referrals from 
the primary care physicians, clinic staff, or the patients themselves. Recruitment occurred 
from July 1999 to August 2001, with a total of 32,908 individuals approached. The 
aforementioned recruitment strategies yielded 2,638 individuals with a positive 
depression screen and an additional 1,626 referred individuals. These potential 
participants subsequently underwent a 60-minute eligibility interview, consisting 
32 
 
 
 
primarily of the SCID diagnostic interview for depression (First et al., 2002). Eligibility 
criteria were minimal. Inclusion criteria were (a) a positive SCID diagnosis for MDD or 
dysthymia, (b) age ≥ 60 years, and (c) intent to use one of the participating clinics as the 
main source of general medical care over the course of the trial (i.e., the next 12 months). 
Exclusion criteria were (a) a current drinking problem (Mayfield, McLeod, & Hall, 
1974), (b) a history of bipolar disorder or psychosis, (c) severe cognitive impairment 
(Callahan, Unverzagt, Hui, Perkins, & Hendrie, 2002), (d) acute risk of suicide, and (e) 
ongoing treatment with a psychiatrist. Based on these eligibility criteria, 2,102 eligible 
individuals were identified, of whom 1,801 enrolled in the trial.  
The present study was a 9-year follow-up of the 235 IMPACT participants 
enrolled from the Indiana sites of the trial (see Figure 2 for a flowchart of participants 
from the Indiana sites). Follow-up data was obtained from the Regenstrief Medical 
Record System (RMRS; McDonald, Tierney, Overhage, Martin, & Wilson, 1992), 
merged with claims data from the Center for Medicare and Medicaid Services (CMS). 
The RMRS, a local electronic medical record system, is one of the largest and longest 
operating systems for capturing, maintaining, and retrieving routine and research-oriented 
clinical data, including registration information, nursing assessments, orders, vital signs, 
laboratory and prescription medication data, and diagnostic and procedural codes 
(McDonald et al., 1992). To provide this data, the RMRS links five health care systems, 
11 acute care hospitals, 13 homeless care sites, and roughly 100 clinics/offices in the 
Indianapolis area (Overhage, McDonald, & Suico, 2000). Additionally, death certificate 
data that includes date and cause of death is routinely obtained from Indiana State 
Department of Health and incorporated into the RMRS. CMS (www.cms.gov) is a federal 
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agency responsible for Medicare and Medicaid, two health insurance programs for adults 
aged ≥ 65 years and for low income families, respectively. CMS enters data regarding 
insurance claims made by Medicare and Medicaid beneficiaries for hospitalization 
expenses, outpatient medical care, and prescription drugs into an analyzable database 
(Hennessy, Leonard, Palumbo, Newcomb, & Bilker, 2007). For the present study, the 
RMRS provided data for years 1978-2009 and CMS for years 1999-2009. The IUPUI 
Institutional Review Board and the CMS Privacy Board approved the use of RMRS and 
CMS follow-up data for the Indiana participants of the IMPACT trial. A waiver of 
consent was obtained to link RMRS and Medicare/Medicaid data. 
 
2.2 Treatment Groups 
After completing the structured baseline interview, participants were randomly 
assigned to one of two groups – either the 12-month IMPACT collaborative care program 
or usual care (Unützer, Katon, et al., 2002). Randomization was stratified by type of 
recruitment (screening or referral) and by clinic. Within each stratum, a random number 
sequence developed using a computer random number generator at the coordinating 
center was used to assign participants to the two groups. A set of numbered, sealed 
envelopes held assignment information in each clinic. When a new patient was enrolled, 
the next sequential envelop was opened.  
 
2.2.1 IMPACT intervention 
Participants in the IMPACT intervention group initially received a 20-minute 
education videotape and a booklet about late-life depression, and they were encouraged 
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to schedule an initial treatment visit with a depression clinical specialist (DCS) at their 
regular primary care clinic (Unützer, Katon, et al., 2002). DCSs were either nurses or 
psychologists, trained according to the IMPACT intervention manual (Unutzer, 1999). At 
the initial treatment visit, DCSs conducted an intake interview, during which they 
assessed patients’ medical and psychosocial history, reviewed psychoeducational 
materials, and discussed patients’ preferences for depression treatment – i.e., 
antidepressant medication or psychotherapy. New participants were discussed during 
weekly team meetings attended by the DCS, a supervising team psychiatrist, and a liaison 
primary care physician. Incorporating patient preferences and feedback from the team 
meetings, the DCS established a depression treatment plan in line with the IMPACT 
treatment algorithm (Unützer, Katon, et al., 2002). This algorithm recommended a 
sequence of treatment steps and was based on depression treatment guidelines that were 
current when the trial was designed (Agency for Health Care Policy and Research 
Depression Guideline Panel, 1993; Lebowitz et al., 1997). Step 1 of the algorithm 
recommended that patients start an antidepressant (usually a SSRI) or a course of 
Problem Solving Treatment in Primary Care (PST-PC; Hegel, Barrett, Oxman, Mynors-
Wallis, & Gath, 1999). PST-PC, a 6-8 session, structured cognitive-behavioral therapy 
for depression, was delivered by the DCSs in the primary care setting. Of the participants 
already receiving antidepressant medications when they entered the study but who had 
not achieved remission were encouraged to augment their treatment with a trial of PST-
PC, whereas nonresponders were encouraged to switch to a different medication, or to 
PST-PC. Individuals who did not respond in 8-12 weeks of the Step 1 treatment plan 
proceeded to Step 2 of the algorithm, which consisted of further augmenting current 
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antidepressant medication with another medication, switching to a different 
antidepressant medication, switching from medication to PST-PC, or from PST-PC to 
medication.  DCSs also discussed these patients during the weekly team meetings, and 
the team psychiatrist met with those patients who presented treatment challenges in the 
patient’s primary care clinic. If after 10 weeks of the Step 2 treatment plan participants 
still had not achieved remission, they were again discussed during the treatment team 
meetings. For these individuals, other treatments were considered, including further 
medication changes or psychotherapy, hospitalization, or electroconvulsive therapy. Of 
note, while the IMPACT algorithm provided guidance in implementing a treatment plan, 
the patient and their primary care provider together made the final treatment choices.  
During the 12-month IMPACT intervention period, patients’ symptoms were 
monitored using the PHQ-9 (Kroenke, Spitzer, & Williams, 2001) and a web-based 
clinical information system (Unützer, Choi, Cook, & Oishi, 2002). DCSs contacted 
patients at least every other week to monitor symptoms, encourage them to schedule 
pleasant life events and adhere to antidepressant regimens, and refer them to additional 
health or social services as needed. Patients who achieved a ≥ 50% reduction in their 
PHQ-9 score and exhibited fewer than 3 of 9 symptoms were considered to be in 
remission. For these patients, DCSs developed a relapse prevention plan and then 
contacted them to follow-up every month thereafter until the end of the intervention 
period.  
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2.2.2 Usual Care 
Patients assigned to the usual care group were notified that they met study criteria 
for a depressive disorder and were encouraged to follow-up with their primary care 
provider, who also  received notification of their patient’s diagnosis and treatment group 
assignment (Unützer et al., 2001). Patients in this group were not restricted in the type of 
care they could receive, including any primary care or specialty mental health treatments. 
They were then observed over the intervention period (Unützer et al., 2001). 
 
2.3 Measures 
2.3.1 Baseline Diabetes 
Because this study focused on the influence of depression treatment on incident 
diabetes, participants with diabetes at baseline (1999-2001) were excluded from all 
analyses. To identify these participants, a Regenstrief data manager first queried the 
RMRS and CMS databases to generate data for each diabetes variable that would be 
considered for inclusion in the baseline diabetes definition (see Table 1). These variables 
were: (1a) diabetes diagnoses – ICD-9 hospital, admitting, primary care, or clinic billing 
code of 250; (1b) diabetes diagnoses – the presence of a diabetes diagnosis in the RMRS 
text fields; (2) diabetes complications – the presence of diabetes-related nephropathy, 
enteropathy, foot ulcer, lipodystrophy, retinopathy, or skin ulcer in the RMRS text fields; 
(3a) diabetes laboratory values – a fasting glucose value ≥ 126 mg/dL (Sacks et al., 
2011); (3b) diabetes laboratory values – an HbA1c value ≥ 8.5%; (4a) diabetes 
medications – prescription for insulin; (4b) diabetes medications – prescription for oral 
hypoglycemic medications; and (5) self-reported diabetes – participants answering ‘yes’ 
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to the IMPACT baseline interview question, “Has a doctor or another health care worker 
diagnosed you with or treated you for high blood sugar or diabetes in the past 3 years?” 
(Unützer, Choi, et al., 2002). Of note, a cut point of  ≥ 8.5% was chosen for HbA1c rather 
than the originally proposed cut point of  ≥ 6.5% because recently published guidelines 
recommend the use of a higher cut point (between 8-9%) for diabetes diagnosis among 
older adults who have comorbid conditions, such as those participating in the IMPACT 
trial (American Geriatrics Society Expert Panel on the Care of Older Adults with 
Diabetes Mellitus, 2013). The midpoint of the recommended range (8.5%) was chosen 
for this study.  
Next, the data manager generated yes/no variables and their corresponding dates 
for each diabetes variable, except (3a) fasting glucose and (3b) HbA1c, for which the data 
manager obtained all values in RMRS during the baseline period (1978-2001). This 
resulted in two separate datasets for fasting glucose and HbA1c values, with multiple rows 
per person. To aggregate this laboratory data, the value closest to participants’ IMPACT 
enrollment date that was at or above the cut point was chosen for each participant and 
coded as ‘1’ (yes). If a participant did not have any values that were at or above the cut 
point, a code of ‘0’ (no) was given. 
Once all yes/no diabetes variables were generated, frequencies were examined 
and compared to expected prevalence rates in the population to ensure that the query 
produced adequate capture of baseline diabetes. When systematically missing data were 
identified during this initial examination (e.g., no fasting glucose data for the years 1994-
1997), the data sources were queried a second time using a more comprehensive set of 
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dictionary terms. Once all data irregularities were resolved, new frequencies were 
examined. Table 1 presents the baseline diabetes variables listed above and their 
respective frequencies.  
Considering all aforementioned baseline diabetes variables, the primary definition 
of baseline diabetes was determined to be the presence of a diabetes diagnosis (ICD-9 
hospital, admitting, primary care, or clinic billing code of 250) and any one of the 
following before participants’ IMPACT enrollment date: (1) a fasting glucose value ≥ 
126 mg/dL; (2) an HbA1c value ≥ 8.5%; or (3) a prescription for diabetes medication 
(insulin or oral hypoglycemic medication). Because this definition required a diabetes 
diagnosis in addition to a positive laboratory value or medication use, it was thought to 
provide the best balance of sensitivity and specificity. The other diabetes variables were 
not utilized due to (a) worse data capture leading to lower than expected prevalence rates, 
(b) inconsistent use in prior studies, and/or (c) poor overlap with other diabetes variables. 
The resultant baseline diabetes variable was a 0/1 variable, where ‘1’ indicated the 
presence of diabetes prior to participants’ IMPACT enrollment date. Participants with a 
‘1’ on this variable (n = 75) were excluded from all analyses.  
 
2.3.2 Incident Diabetes 
To identify the participants who developed diabetes during the follow-up period, 
RMRS and CMS databases were again queried to obtain the following incident diabetes 
variables (see Table 2): (1a) diabetes diagnoses – ICD-9 hospital, admitting, primary 
care, or clinic billing code of 250; (1b) diabetes diagnoses – the presence of a diabetes 
diagnosis in the RMRS text fields; (2) diabetes complications – the presence of diabetes-
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related nephropathy, enteropathy, foot ulcer, lipodystrophy, retinopathy, or skin ulcer in 
the RMRS text fields; (3a) diabetes laboratory values – a fasting glucose value ≥ 126 
mg/dL (Sacks et al., 2011); (3b) diabetes laboratory values – an HbA1c value ≥ 8.5%; (4a) 
diabetes medications – prescription for insulin; (4b) diabetes medications – prescription 
for oral hypoglycemic medications.  
Similar to the baseline diabetes variables, the data manager (who was blind to 
treatment assignment) generated yes/no incident diabetes variables and their 
corresponding dates, except for (3a) fasting glucose, and (3b) HbA1c, for which the data 
manager obtained all values in RMRS during the follow-up period. Again, this resulted in 
two separate datasets for fasting glucose and HbA1c values, with multiple rows per 
person. To aggregate this data, the earliest value during the follow-up period that was at 
or above the cut point was chosen for each participant and coded as ‘1’ (yes). If a 
participant did not have any values that were at or above the cut point, the earliest value 
during the follow-up was chosen and coded as ‘0’ (no). Once all yes/no variables were 
generated, frequencies were examined and compared to expected incidence rates in the 
population. Table 2 presents the incident diabetes variables listed above and their 
respective frequencies. 
Consistent with the baseline definition, the primary outcome was defined as the 
first occurrence of a diabetes diagnosis (ICD-9 hospital, admitting, primary care, or clinic 
billing code of 250) and any one of the following during the period between participants’ 
IMPACT enrollment and December 31, 2009: (1) a fasting glucose value ≥ 126 mg/dL; 
(2) an HbA1c value ≥ 8.5%; or (3) a prescription for diabetes medication (insulin or oral 
hypoglycemic medication). This resulted in a 0/1 variable, where ‘1’ indicated incident 
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diabetes. To code the date associated with an incident diabetes event, first the earliest 
date among (1), (2) and (3) was chosen and compared to the date of a participant’s ICD-9 
diabetes diagnosis. Then, the latest date of the two was chosen because the incident 
diabetes definition required both components to be present. Of note, participants were 
followed until December 31, 2009, because CMS data were available locally up until this 
date. The total follow-up time was between 8.5 and 10.5 years.  
Both RMRS and CMS data are used extensively in epidemiologic, clinical, health 
services, and policy research and are valid data sources (Hennessy et al., 2007; Platt & 
Ommaya, 2005; Ray, 1997). For example, the validity of vital status in the RMRS and 
CMS appears to be very good; 97% of individuals have the same vital status in the two 
databases (Hennessy et al., 2007). Moreover, CMS data demonstrate infrequent obvious 
diagnostic miscoding, stable counts of prescription claims over time, and a high 
proportion of valid drug codes on prescription records (Hennessy et al., 2007). Lastly, a 
recent study examining the validity of billing and hospital discharge diagnoses in a 
claims database similar to CMS revealed that sensitivity for diabetes diagnosis was 
acceptable (64%) and specificity was excellent (97%) (Wilchesky, Tamblyn, & Huang, 
2004). 
 
2.3.3 Other Variables 
During the IMPACT baseline interview, patients were asked by trained lay 
interviewers about demographic information (age, sex, race/ethnicity) and if they had 
been diagnosed or treated for any of 10 common chronic medical problems in the 
preceding 3 years, including diabetes and hypertension (Unützer et al., 2001). Data 
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regarding baseline smoking status and BMI were obtained through RMRS. Several 
indicators of smoking status were obtained, including any smoking diagnoses, yes/no 
markers for current smoking status, and packs-per-day information. If any of these 
indicators was positive, the participant received a code of ‘1’ (yes) on smoking status; 
otherwise, the participant received a code of ‘0’ (no). Height and weight information was 
also obtained from RMRS. BMI was calculated as weight in kilograms divided by the 
square of height in meters (kg/m2). 
Depression variables assessed during the baseline interview were depressive 
symptom severity and participants’ use of antidepressants in the preceding 3 months. 
Depression symptom severity was assessed using the 20 depression items of the 
Symptom Checklist-90 (SCL-20; Derogatis, Lipman, & Covi, 1973; Unützer et al., 
2001). The SCL-20 is a widely used outcome measure in primary care trials (Katon et al., 
1999; Katon et al., 1995; Kroenke et al., 2001; Williams Jr et al., 2000). The measure has 
demonstrated good internal consistency in previous studies (Cronbach’s α = 0.84-0.86) 
(Lee, Schulberg, Raue, & Kroenke, 2007; Williams, Stellato, Cornell, & Barrett, 2004), 
as well as in the IMPACT sample recruited from the Indiana sites (Cronbach’s α = 0.81 at 
baseline and 0.91 at 12 months). In terms of validity, the SCL-20 and PHQ-9, which is an 
established depression measure, have been found to be moderately correlated with one 
another (r = 0.54). In addition, a 50% reduction in SCL-20 score has been shown to 
accurately identify 79% of patients who no longer met criteria for MDD after 12 weeks 
of collaborative care, suggesting that this cut point is a good indicator of change in 
depression status (O'Connor et al., 2010). Participants who endorsed use of 
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antidepressants in the 3 months preceding the baseline interview received a code of ‘1’ 
(yes) on this variable; otherwise, participants received a code of ‘0’ (no).  
After the baseline interview, follow-up assessments occurred at 3-, 6-, and 12-
months of the intervention period. These interviews were conducted over the telephone 
by trained lay interviewers (Unützer, Katon, et al., 2002) who were blind to treatment 
assignment. Response rates for the telephone interviews were 90%, 87%, and 83% for the 
3-, 6-, and 12-month calls, respectively (Unützer, Katon, et al., 2002). Depression 
outcome and care variables assessed during the 12-month telephone call were depressive 
symptom severity, as well as antidepressant use and psychotherapy received during the 
intervention period (Unützer, Katon, et al., 2002). To assess depression symptom 
severity, interviewers readministered the SCL-20. Participants who endorsed taking any 
antidepressants during the 12-month intervention period were coded as ‘1’ (yes), and the 
percentage in each treatment group who received antidepressants during the trial was 
calculated. Participants who endorsed having any psychotherapy sessions during the 
intervention period were coded as ‘1’ (yes), and the percentage in each treatment group 
who received psychotherapy during the trial was calculated. Change in depressive 
symptom severity over the intervention period was calculated as 12-month SCL-20 score 
minus baseline SCL-20 score. 
 
2.4 Data Analysis 
2.4.1 Data Cleaning and Reduction 
All variables were examined for missing values. Missing data (n = 4 per treatment 
group) were identified only for the 12-month SCL-20 score. Because no missing data 
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were imputed, analyses that included the 12-month SCL-20 score or SCL-20 change 
variables had a total sample size of 152 participants.  
Next, frequencies for categorical variables (sex, race/ethnicity, hypertension, 
smoking status, antidepressant use during the 3 months preceding baseline, and 
antidepressant use and psychotherapy during the trial) and means, standard deviations, 
and distributions of continuous variables (age, BMI, and pre-treatment, post-treatment, 
and change in SCL-20 score) were examined to ensure that these descriptive statistics 
were in the expected ranges. All values were found to be within range. For continuous 
variables, skewness and kurtosis values were also examined to evaluate the assumption of 
normality. Because all variables were normally distributed (skewness < 3.0 and kurtosis 
< 10.0; Kline, 2010), no transformations were performed. 
 
2.4.2 Preliminary Analyses 
Prior to conducting any hypothesis-testing analyses, chi-square tests (for 
categorical variables) and independent samples t tests (for continuous variables) were 
conducted to compare baseline characteristics between patients in the IMPACT and usual 
care groups. Given that randomization was not stratified by baseline diabetes status, it 
was especially important to evaluate whether there was covariate imbalance between the 
groups at baseline, as such imbalance could have suggested an alternative explanation for 
an apparent treatment effect. For instance, a treatment group difference in diabetes 
incidence could be due to an imbalance in one or more baseline variables predictive of 
future diabetes (e.g., BMI). Additionally, a Cohen’s d effect size was calculated to 
quantify the effect of the IMPACT intervention on change in SCL-20 score.  
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2.4.3 Test of Hypothesis #1 
Hypothesis #1: Depressed patients randomized to collaborative depression care 
have a lower incidence of type 2 diabetes than depressed patients randomized to usual 
care. 
To test this hypothesis, Cox proportional hazard regression models were 
constructed. Cox models are a type of survival analysis that take into account the 
differing times to an event of interest and compare the cumulative probability of events 
occurring in two or more cohorts (Singh & Mukhopadhyay, 2011). Cox models yield 
hazard ratios (HR) as the primary statistic. For this study, HRs estimated the relative 
likelihood of incident diabetes in the IMPACT group versus control group. Patients were 
censored at their date of death or at the end of the follow-up period (December 31, 2009). 
Tests of the proportional hazards assumption were made using Schoenfeld residuals. 
Specifically, correlations between partial residuals of each covariate and rank ordered 
survival time were evaluated. All correlations were nonsignificant indicating that the 
proportional hazards assumption was met for each variable. These analyses were 
supplemented by examining Kaplan-Meier method plots. Specifically, plots of the log-log 
survival curves of time by each covariate were assessed for linearity. All relationships 
were linear, again indicating that the assumption was met for each variable. 
 For hypothesis #1, Cox models were constructed to test whether there were 
treatment group differences in the cumulative likelihood of incident diabetes over the 9-
year period. The first Cox model included the randomization status variable (IMPACT 
vs. usual care) as the only independent variable (no covariates). Kaplan-Meier survival 
curves were constructed to illustrate the time from enrollment to incident diabetes for 
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each treatment group. The second Cox model included baseline age, sex, and 
race/ethnicity variables in addition to the randomization status variable (demographics-
adjusted analyses), while the third Cox model further included baseline hypertension, 
smoking, and BMI as diabetes risk factors (Grundy et al., 2005; Mozaffarian et al., 2009) 
(diabetes risk factors-adjusted analyses). Then, subsequent models were constructed in 
which baseline variables that were significantly or meaningfully imbalanced between the 
treatment groups were added one at a time to the first Cox model that included the 
randomization status variable. The last set of Cox models were those that added the 
depression treatment variables (SCL-20 change, trial antidepressants, and trial 
psychotherapy) one at a time to the first Cox model.  
 
2.4.3.1 Sensitivity Analyses 
To examine the influence of the primary incident diabetes definition on the 
pattern of results, the demographics-adjusted and diabetes risk factors-adjusted analyses 
described in the preceding section were rerun after modifying the outcome definition. 
The alternative definitions were (a) secondary definition – the presence of any one of the 
following: ICD-9 code of 250, fasting glucose value ≥ 126 mg/dL, HbA1c value ≥ 8.5%, 
or diabetes medication (insulin or oral hypoglycemic medication); (b) ICD-9 code of 250 
alone; (c) fasting glucose value ≥ 126 mg/dL alone; (d) HbA1c value ≥ 8.5% alone; and 
(e) diabetes medication (insulin or oral hypoglycemic medication) alone. Of note, to code 
the date associated with a diabetes event identified by definition (a), the earliest date 
among the four components (ICD-9 code, fasting glucose, HbA1c, or diabetes medication)  
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during the follow-up period was chosen. For all alternative outcome definitions, 
participants who did not have an event were censored at their date of death or at the end 
of the follow-up period (December 31, 2009).   
To examine the influence of the primary definition of baseline diabetes on the 
pattern of results, a secondary definition of baseline diabetes was created, defined as the 
presence of any one of the following: ICD-9 code of 250, fasting glucose value ≥ 126 
mg/dL, HbA1c value ≥ 8.5%, or diabetes medication (insulin or oral hypoglycemic 
medication). Using this broad definition of baseline diabetes, the unadjusted, 
demographics-adjusted, and diabetes risk factors-adjusted analyses were rerun with both 
the primary and alternative outcome definitions. 
Finally, to examine the influence of our chosen cutpoint for HbA1c , the primary 
definition for baseline diabetes, and all outcome definitions for diabetes were modified to 
reflect a cutpoint for HbA1c of ≥ 8.0%, which represents the more conservative end of the 
range (between 8-9%) for diabetes diagnosis recommended for older adults in recently 
published guidelines (American Geriatrics Society Expert Panel on the Care of Older 
Adults with Diabetes Mellitus, 2013). All analyses were then rerun using these modified 
baseline and outcome definitions. 
 
2.4.4 Test of Hypotheses #2-4 
Hypothesis #2: Change in depressive symptoms during the trial mediates the 
hypothesized beneficial effect of collaborative depression care on incident diabetes.  
Hypothesis #3: Antidepressant treatment received during the trial mediates the 
hypothesized beneficial effect of collaborative depression care on incident diabetes.  
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Hypothesis #4: Psychotherapy received during the trial mediates the hypothesized 
beneficial effect of collaborative depression care on incident diabetes. 
To test hypotheses #2-4, three separate mediation models were constructed. 
Specifically, 12-month change in SCL-20 score, trial antidepressants (yes, no), and trial 
psychotherapy (yes, no) were added one at a time to Cox models that included the 
treatment main effect (randomization status variable). Percent reduction in treatment 
effect size after adding each potential mediator was computed as (BT+M – BT) / BT x 100, 
where BT+M is the unstandardized coefficient for the treatment main effect in the model 
with the potential mediator, and BT is the unstandardized coefficient for the same variable 
in the model without the mediator. These descriptive results help characterize the degree 
to which the treatment effect is explained by each potential mediator. Statistical 
mediation analyses were then performed using the SPSS macro known as ‘PROCESS’ 
(Hayes, 2012; Preacher & Hayes, 2008). Confidence intervals were obtained using 
nonparametric bootstrapping methods. In bootstrapping, random samples are generated 
based on the original data (in the current analyses, 5,000 random samples were 
generated). For each random sample, the mediated effects are computed. The distribution 
of these effects is used to obtain 95% confidence intervals for the magnitude of indirect 
effect. The significance of the indirect effect can be determined by assessing whether the 
confidence interval contains the value ‘0’. All analyses were performed using SPSS 
statistical software, version 21 (IBM Corp., Armonk, NY).
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CHAPTER 3 RESULTS 
 
3.1 Characteristics of Participants 
The 75 participants with diabetes at baseline were excluded from the sample 
comprised of the 235 participants randomized from the Indiana sites in the IMPACT trial, 
resulting in a final sample of 160 participants that were equally distributed between 
IMPACT and usual care groups (see Figure 2 for flowchart of participants). The mean 
age of the total sample was 67 years (SD = 6.9). Twenty-three percent were male, and 
almost half (44%) were African-American. There was a high prevalence of diabetes risk 
factors at baseline, as 72% had hypertension, 36% were smokers, and 42% were obese 
(BMI ≥ 30). At baseline, 12% patients met criteria for MDD only, 35% for dysthymic 
disorder only, and 53% for both MDD and dysthymic disorder. The mean baseline SCL-
20 score was 1.37 (SD = 0.53), indicating moderate depressive symptom severity. In the 
3-months preceding the baseline interview, 51.9% of the sample reported taking 
antidepressants. Table 3 presents these baseline characteristics stratified by treatment 
group. Although independent sample t tests and chi-square tests revealed no significant 
group differences in these characteristics, mean BMI was numerically higher (p = .137) 
and mean SCL-20 score was numerically lower (p = .074) in the IMPACT group versus 
the usual care group.
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3.2 Effect of the IMPACT Intervention on Depression Outcomes and Care 
As can be seen in Table 3 and Figure 3, IMPACT patients without baseline 
diabetes exhibited significantly greater reductions in SCL-20 score than usual care 
patients (p = .013) at post-treatment, with a treatment effect size (d = 0.41) in the 
moderate range (Cohen, 1992). Moreover, 29% (23/80) of the IMPACT patients, versus 
15% (12/80) of the usual care patients, achieved at least a 50% reduction in SCL-20 score 
(p = .035), which was the primary outcome by which treatment response was assessed in 
the entire IMPACT trial. As is also shown in Table 3, IMPACT patients were more likely 
to have received any psychotherapy during the trial than usual care patients (p <.001), 
although they were not significantly more likely to have had antidepressant use during 
the trial (p = .230). 
 
3.3 Test of Hypothesis #1 
Assessing incident diabetes with the primary definition (the presence of an ICD-9 
diabetes code and either a positive laboratory value or diabetes medication use), 33 cases 
(21%) were identified during the 9-year follow-up period, of which 49% (n=16) were a 
combination of an ICD-9 code and a positive fasting glucose value, 30% (n=10) were a 
combination of an ICD-9 code and positive HbA1c value, and 21% (n=7) were a 
combination of an ICD-9 code and diabetes medication use. Table 4 shows the event 
composition of the primary definition of incident diabetes in each treatment group. As 
can be seen, the IMPACT group was more likely than the usual care group to have 
received a diabetes diagnosis through a combination of an ICD-9 code and a positive 
laboratory value.  
50 
 
 
 
Contrary to Hypothesis #1, the rate of incident diabetes in the IMPACT group 
(22/80 = 27.5%) was twice the rate observed in the usual care group (11/80 = 13.7%). 
Figure 4 displays the Kaplan-Meier survival curves illustrating the time to incident 
diabetes for each treatment group. As can be seen, the survival curves separated early in 
the follow-up period, and the advantage of the usual care group continued to increase in 
magnitude from year 2 to year 9 of follow-up. However, a log-rank test indicated that this 
apparent group difference fell short of significance (χ2 = 3.27, p = .071). 
As shown in Table 5 (primary definition), a Cox model with the randomization 
status variable as the only independent variable also indicated that IMPACT patients had 
a numerically (94%), though nonsignificant (p = .076), increased risk of incident diabetes 
compared to usual care patients. In subsequent models, IMPACT patients remained at a 
nonsignificant increased risk of incident diabetes after adjusting for demographic factors 
(94% increased risk, p = .075) and further adjusting for diabetes risk factors (73% 
increased risk, p = .157). In the model with all covariates, only BMI significantly 
predicted incident diabetes (HR = 1.08, 95% CI: 1.04-1.12, p < .001). Specifically, a 1-
unit increase in BMI was associated with an 8% increase in the likelihood of incident 
diabetes.  
Because baseline SCL-20 score and BMI variables were noticeably imbalanced 
between the treatment groups, they were added one at a time to models that included the 
randomization status variable. When baseline SCL-20 score was added, IMPACT 
patients remained at a numerically, though nonsignificant, increased risk of incident 
diabetes (HR = 2.06, 95% CI: 0.98-4.31, p = .056) compared to usual care patients. In this 
model, baseline SCL-20 score (HR = 1.35, 95% CI: 0.72-2.54, p = .345) did not predict 
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incident diabetes. When BMI was added, the effect size for randomization status was 
attenuated (HR = 1.64, 95% CI: 0.78-3.43, p = .192), and BMI significantly predicted 
incident diabetes (HR = 1.06, 95% CI: 1.03-1.10, p < .001). This BMI-adjusted analysis 
suggests that the numerically higher mean BMI of the IMPACT group than the usual care 
group at baseline may have, in part, contributed to the elevated rate of incident diabetes 
in the IMPACT group. 
Then, depression treatment variables (SCL-20 change, trial antidepressants, and 
trial psychotherapy) were added one at a time to models that included the randomization 
status variable. In each of these three models, neither randomization status nor any of the 
depression treatment variables was significantly associated with incident diabetes (SCL-
20 change model – randomization status: HR = 1.79, 95% CI: 0.84-3.78, p = .129; SCL-
20 change: HR = 0.92, 95% CI: 0.54-1.58, p = .771; trial antidepressants model – 
randomization status: HR = 1.84, 95% CI: 0.88-3.81, p = .104; trial antidepressants: HR = 
2.15, 95% CI: 0.82-5.60, p = .117; trial psychotherapy model – randomization status: HR 
= 1.66, 95% CI: 0.75-3.68, p = .211; trial psychotherapy: HR = 1.44, 95% CI: 0.68-3.04, 
p = .339). Collectively, these findings do not support Hypothesis #1. 
 
3.3.1 Sensitivity Analyses 
 Table 5 presents the number of incident diabetes cases identified using each of the 
five alternative outcome definitions. There was variability in the rate of incident diabetes 
across these definitions, ranging from 13 events (IMPACT = 9; usual care = 4) for the 
HbA1c only definition to 67 events (IMPACT = 37; usual care = 30) for the secondary 
definition (ICD-9 code OR fasting glucose OR HbA1c OR diabetes medication). Across 
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the outcome definitions, there was also variability in the treatment group differences in 
incident diabetes rates, with the lowest treatment group difference observed for diabetes 
medication only definition (IMPACT = 13.7%; usual care = 10.0%), and the highest for 
the fasting glucose only definition (IMPACT = 38.7%; usual care = 25.0%). 
In Cox models that included randomization status as the only independent 
variable, IMPACT patients had a nonsignificantly elevated risk (23% to more than two 
times the increased risk) of incident diabetes (see Table 5). The lowest and highest HRs 
were observed for the secondary definition (HR = 1.23, 95% CI: 0.76-1.99, p = .399) and 
for the HbA1c only outcome (HR = 2.15, 95% CI: 0.66-7.00, p = .202), respectively. In 
subsequent models, IMPACT patients remained at a nonsignificant increased risk of 
incident diabetes after adjusting for demographic factors (20% to more than two times the 
increased risk) and further adjusting for diabetes risk factors (9% to 65% increased risk; 
see Table 5). In Cox models that adjusted for demographic factors, the lowest and highest 
HRs were again observed for the secondary definition (HR = 1.20, 95% CI: 0.74-1.96, p 
= .454) and the HbA1c only outcome (HR = 2.12, 95% CI: 0.65-6.98, p = .215), 
respectively. Lastly, in Cox models further adjusting for diabetes risk factors, the lowest 
and highest HRs were observed for ICD-9 code only outcome (HR = 1.09,95% CI: 0.59-
2.00, p = .781) and the HbA1c only outcome (HR = 1.65, 95% CI: 0.47-5.75, p = .429), 
respectively. These sensitivity analyses suggest that the relationship between depression 
treatment and incident diabetes events does not vary by the type of diabetes outcome 
definition used, although the nonsignificant elevation in risk for the IMPACT group does 
vary numerically across the definitions. Although the treatment group difference is 
consistently larger for the HbA1c only outcome, the low event rate and large confidence 
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intervals for this outcome render interpretation difficult. It should be noted that across the 
diabetes definitions assessed, adjusting for BMI reduced the treatment group difference, 
again implicating the baseline BMI imbalance as a partial explanation for the elevated 
incidence rate in the IMPACT group. Taken together, these sensitivity analyses do not 
support Hypothesis #1. 
Using the broad definition of baseline diabetes [any one of the following: ICD-9 
code of 250, fasting glucose value ≥ 126 mg/dL, HbA1c value ≥ 8.5%, or diabetes 
medication (insulin or oral hypoglycemic medication)] resulted in a cohort of 120 
participants (IMPACT: n=60; Usual Care: n=60). Table 6 presents the number of incident 
diabetes cases identified in this smaller cohort using each of the five alternative outcome 
definitions. There was again variability in the rate of incident diabetes across these 
definitions, ranging from 6 events (IMPACT = 6; usual care = 0) for the HbA1c only 
definition to 40 events (IMPACT = 23; usual care = 17) for the secondary definition 
(ICD-9 code OR fasting glucose OR HbA1c OR diabetes medication). There was also 
variability in the treatment group differences in incident diabetes rates, with the lowest 
and highest treatment group differences observed for the HbA1c only definition (IMPACT 
= 5.0%; usual care = 0.0%) and the primary definition (IMPACT = 20.0%; Usual Care = 
6.7 %) respectively. Overall, IMPACT patients remained at nonsignificant increased risk 
of incident diabetes in unadjusted (35% for the secondary definition to nearly three times 
the increased for the primary definition), demographic factors-adjusted (38% for the 
secondary definition to nearly five times the increased risk for the diabetes medication 
only definition), and diabetes risk factor-adjusted (17% for the fasting glucose only 
definition to more than 5 times the increased risk for the diabetes medication only 
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definition) analyses. Across all analyses, these low event rates and large confidence 
intervals continue to render interpretation difficult, but suggest that the relationship 
between depression treatment and incident diabetes events does not vary by the type of 
diabetes baseline definition used. These sensitivity analyses do not support Hypothesis 
#1. 
Finally, using a more conservative HbA1c cutpoint of ≥8% resulted in a cohort of 
159 participants (IMPACT: n=79; Usual Care: n=80). As can be seen in Table 7, the 
number of total incident diabetes events (33), those for each of the five alternative 
outcome definitions, as well as the pattern of results for unadjusted, demographic factors-
adjusted, and diabetes risk factor-adjusted all remained similar to those reported in Table 
5. The one exception was the slightly greater number of incident diabetes events for the 
HbA1c only outcome (16; IMPACT: n=10; Usual Care; n=6) due to the use of the lower 
end of the HbA1c range (8%). This slightly greater number of events however did not 
change the pattern of results for the HbA1c only outcome analyses. 
 
3.4 Test of Hypothesis #2-4 
 Hypotheses #2-4 posited that change in depressive symptoms (Hypothesis #2), 
antidepressant treatment received (Hypothesis #3), and psychotherapy received 
(Hypothesis #4) during the trial would mediate the hypothesized beneficial effect of 
collaborative depression care on incident diabetes. These analyses, which were dependent 
on the outcome of Hypotheses #1, were not conducted for the following critical reason: 
the analyses for Hypothesis #1 indicated no beneficial effect of collaborative depression 
care on incident diabetes. In other words, Hypotheses #1 was not supported. It should be 
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noted that, under normal circumstances, a significant path ‘c’ (depression treatment to 
incident diabetes) association is not required to test for mediation effects (Hayes, 2012). 
However, in this instance, IMPACT patients had a nonsignificantly elevated risk of 
incident diabetes compared to usual care patients. Because the treatment effect was found 
to be trending in the opposite direction of that hypothesized in Hypothesis # 1, there is no 
theoretical rationale to pursue Hypotheses #2-4. Had the treatment effect been in the 
expected direction but falling short of statistical significance, mediation analyses testing 
Hypotheses #2-4 would have been conducted as proposed.
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CHAPTER 4 DISCUSSION 
 
4.1 Summary of Study Findings 
The primary objective of this follow-up study was to examine the effect of a 12-
month collaborative care program for late-life depression on the 9-year risk of incident 
diabetes among depressed older adults initially free of diabetes. To achieve this objective, 
a unique combination of resources was examined – namely, IMPACT trial data linked 
with electronic medical record data and Medicare/Medicaid data.  The IMPACT trial 
found that 45% of the intervention patients, versus 19% of the usual care patients, 
achieved a 50% reduction in depressive symptom severity at 12-month follow-up 
(Unützer, Katon, et al., 2002). These positive results, combined with the other available 
data sources, made possible the evaluation of the long-term effect of successful 
depression treatment on incident diabetes. This study had the potential to identify 
depression as a modifiable risk factor for diabetes and, consequently, depression 
treatment as a new target of diabetes prevention efforts.  
Before testing the study hypotheses, it was important to exclude participants with 
diabetes at baseline. Thus, seventy-five of the 235 (32%) participants from the Indiana 
sites of the IMPACT trial were excluded. This prevalence of baseline diabetes is 
comparable to that found among older adults in the U.S. (Go et al., 2013). Importantly, 
excluding these participants (n = 40 from the IMPACT arm, n = 35 from the usual care 
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group) did not appear to imbalance the treatment groups with respect to sample size or 
baseline characteristics. After these exclusions, 80 participants remained each treatment 
group. Additionally, although baseline BMI was numerically higher and baseline SCL-20 
score was numerically lower in the IMPACT group, there were no significant differences 
in baseline characteristics between the treatment groups. Nonetheless, it should be kept in 
mind that randomization in the IMPACT trial was not stratified by baseline diabetes 
status, leaving open the possibility that the treatment groups had imbalance on key 
factors, which may not have been measured. 
Similar to the entire IMPACT trial (Unützer, Katon, et al., 2002) and other 
depression trials of older adults (Katon et al., 2004), IMPACT patients without baseline 
diabetes exhibited significantly greater reductions in depressive symptoms than usual 
care patients and were also more likely to have had any psychotherapy during the trial. 
However, there was no significant difference between groups in antidepressant use during 
the trial. It is worth mentioning that the questions assessing the type of treatment received 
during the intervention period were yes-no questions. This type of assessment does not 
provide any information about the quality and quantity of treatment received, such as the 
number of psychotherapy sessions completed, and the dose and duration of 
antidepressants received during the trial. The assessment of antidepressant use is a 
particularly important issue because it may have masked key differences between groups. 
Even though the rate of antidepressant medication use was similarly high in both 
treatment groups, patients in the usual care group may have received an inadequate dose 
and duration, which is often the case in primary care settings (Simon, 2002). In contrast, 
patients in the IMPACT group may have received the dose and duration of antidepressant 
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treatment consistent with clinical recommendations. Together, the higher likelihood of 
receiving psychotherapy and perhaps of receiving the recommended antidepressant 
treatment may be responsible for the greater reductions in depressive symptoms observed 
in the IMPACT group versus the usual care group. 
Despite improvement in depressive symptoms, the primary hypothesis 
(Hypothesis #1) that depressed patients randomized to collaborative depression care, 
versus usual care, would have a lower incidence of type 2 diabetes was not supported. 
Cox model results showed no significant treatment group differences in incident diabetes 
before and after adjustment for demographic and diabetes risk factors, and in sensitivity 
analyses in which alternative definitions of incident diabetes were modeled. Collectively, 
these analyses suggest that depression treatment alone did not have much influence on 
long-term diabetes incidence. In fact, the rate of incident diabetes in the IMPACT group 
was twice that in the usual care group, with Cox models confirming that the IMPACT 
group had a nonsignificantly elevated risk (94%). In all models, adjusting for BMI 
attenuated the nonsignificantly elevated treatment group difference and BMI was a 
significant predictor of incident diabetes, suggesting that the baseline BMI imbalance 
may have contributed to the elevated rate of incident diabetes in the IMPACT group. 
Across alternative outcome definitions modeled in sensitivity analyses, the degree of 
nonsignificant elevation of the IMPACT group varied numerically, with the greatest 
treatment group difference observed for the HbA1c only outcome. Finally, Cox models 
adjusting for depression treatment variables did not change the pattern of results and none 
of these depression variables were associated with incident diabetes. Given the absence 
of any support for Hypothesis #1, I did not pursue analyses evaluating change in 
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depressive symptoms and antidepressants and psychotherapy received during the trial as 
potential mediators of the beneficial effect of collaborative depression care on incident 
diabetes (Hypotheses #2-4). To summarize, the findings of this long-term follow-up of 
the IMPACT trial suggest that depression treatment alone is not sufficient to lower the 
diabetes risk of older depressed patients.  
 
4.2 Fit with Existing Literature 
The present results are both inconsistent and consistent with the existing 
literature. These findings are inconsistent with considerable epidemiologic evidence 
suggesting that depression is an independent risk factor for diabetes (see ‘Epidemiologic 
studies’ section in the Introduction), and they do not align with results of some past 
clinical studies involving non-diabetic samples. In two separate studies conducted by 
Weber-Hamann et al. (2006, 2008), patients with depression but not diabetes who were 
given either tricyclic or SSRI antidepressants and who achieved remission showed 
improved insulin sensitivity over a 5- to 8-week period. It should be noted, however, that 
in the larger of these two studies, depression remission was positively associated with 
only one of three diabetes outcomes examined (insulin concentration 120 minutes after a 
glucose ingestion challenge but not fasting insulin and glucose levels). In another study, 
Okamura et al. (2000) reported that non-diabetic patients with depression who received 
either tricyclic or tetracyclic antidepressants showed significant improvement in insulin 
sensitivity from pre- to post-treatment, as assessed by oral glucose tolerance tests. Yet, 
because all three studies did not include a control group, it is unclear if the same pattern 
of results would have been found if patients receiving antidepressant therapy were 
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compared to those receiving placebo or usual care. The present results are consistent with 
those of Kauffman et al. (2005), who showed that 8 weeks of an SSRI treatment did not 
produce improvement in insulin sensitivity, as measured by oral glucose tolerance tests. 
Yet, these results are not easily comparable to those of the present study because of their 
dissimilar sample of 32 depressed and nondepressed women of reproductive age who 
were euglycemic at baseline. This discussion highlights the dearth of past studies 
involving samples of depressed patients initially free of diabetes and illustrates the lack 
of methodological rigor of these studies (e.g., small sample size, lack of randomization, 
and absence of a control group). Despite the null findings, the present study contributes to 
this limited literature by: (a) utilizing data from a well-designed clinical trial in which 
participants were randomized to intervention arms, (b) excluding participants with 
diabetes at baseline, and (c) including a long follow-up period to identify cases of 
incident diabetes. 
Interestingly, the present results also parallel those of some studies involving 
patients with comorbid depression and diabetes. In this literature, only 1 in 4 previous 
trials have found a significant association between effective depression treatment and 
indices of glycemic control (see ‘Treatment studies’ section in the Introduction). 
Moreover, of the studies that did find improvement in glycemic control, several also 
included diabetes self-management training in addition to cognitive-behavioral therapy or 
supportive therapy for depression (Van der Feltz-Cornelis et al., 2010). Due to the 
combination of interventions, it is unclear whether depression treatment, diabetes self-
management training, or both were responsible for the improvement in glycemic control. 
Of note, among the studies that reported null findings is a study that also utilized data 
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from the IMPACT trial (Williams et al., 2004). In a preplanned subgroup analysis of 417 
participants with both depression and diabetes, it was found that, although HbA1c levels 
decreased slightly (7.28% to 7.11%), the IMPACT intervention did not significantly 
improve glycemic control.  
Although investigators have proposed several explanations for these null findings, 
they do not appear to be applicable to the present study. For instance, one proposed 
explanation is that the post-treatment assessment of glycemic control may have been 
premature if improvement in glycemic control lags behind improvement in depressive 
symptoms. This explanation is not applicable here, given the 9-year follow-up period. 
Another potential explanation is that there was limited margin to detect improvement in 
glycemic control due to good glycemic control at baseline. Again, this explanation does 
not seem applicable here, as IMPACT participants had an elevated risk of type 2 diabetes 
due to their older age and high diabetes risk factor burden. Nonetheless, there are other 
plausible explanations for the null results of the present study, which are discussed in the 
next section.  
 
4. 3 Possible Explanations for Numerically Elevated Diabetes Risk in the Treatment Arm 
There are at least three possible explanations for the numerically, although 
nonsignificantly, elevated diabetes risk in the IMPACT group. One possible explanation 
is the numerically higher BMI at baseline in the IMPACT group (31.1) versus the usual 
care group (29.1). Due to this higher BMI, the degree of insulin resistance and the 
prevalence of pre-diabetes may have been greater in the IMPACT group. Thus, it is 
reasonable that a higher percentage of patients in this arm would transition to diagnosed, 
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clinical diabetes during follow-up. The BMI-adjusted analyses provide some support for 
this notion, as adjusting for baseline BMI attenuated the numerically elevated diabetes 
risk of the IMPACT group across models (see Table 5). Also of relevance, baseline BMI 
predicted incident diabetes.  However, this adjustment did not eliminate the numerically 
elevated diabetes risk of the IMPACT group, suggesting that other factors are also 
involved. 
Another possible explanation is the potential detrimental side effects of 
antidepressant medication on insulin resistance and type 2 diabetes. Specifically, one 
direct physiologic effect of SSRIs – the primary type of antidepressant medication 
received by participants – is appetite promotion and weight gain (Ferguson, 2001). In 
turn, weight gain exacerbates insulin resistance and, subsequently, can lead to the 
development of type 2 diabetes (Ismail, 2010). Thus, if the IMPACT group did receive a 
higher dose and longer duration of SSRI treatment, it may have promoted the 
development of diabetes. Results from the present study, although providing some 
support for this explanation, also suggest that antidepressant use alone does not explain 
the higher diabetes incidence in the IMPACT group. On the one hand, antidepressant use 
during the trial was associated with a numerically, though nonsignificantly, higher risk of 
incident diabetes (HR = 2.15). On the other hand, adjusting for antidepressant use during 
the trial only slightly attenuated the treatment effect on incident diabetes (from HR = 1.94 
to HR = 1.84). 
A related possibility is that successful depression treatment in the IMPACT arm 
may have had detrimental effects on obesity as a primary hypothesized mechanism 
underlying the depression-to-diabetes relationship. Specifically, it is possible that 
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alleviation of depression may have resulted in increased appetite and caloric intake in a 
fashion similar to the weight promoting consequences of smoking cessation. This weight 
gain in the IMPACT arm may have led to obesity and diabetes development at a greater 
rate over the follow-up period.  
  A third possible explanation is that the increased incidence of diabetes in the 
IMPACT group is due to greater detection of diabetes in this group. First, IMPACT 
patients had greater contact with health care providers (DCSs contacted patients at least 
every other week) and were probably more likely to have been referred for other 
health/social services when indicated (which was one of the DCS's tasks). Greater contact 
with the health care system could have led the IMPACT group to have an increased 
chance of being assessed for new-onset medical conditions, including diabetes. 
Consistent with this notion, 19 of the 22 (86%) diabetes cases in the IMPACT group, 
versus only 7 of the 11 (64%) diabetes cases in the usual care group were due to the 
presence of a diabetes ICD-9 code and a positive laboratory value, suggesting that 
laboratory tests may have been conducted more often in the IMPACT group. Second, 
IMPACT patients exhibited greater improvements in depression during the trial and may 
have had a lower rate of depression relapse during follow-up due to receiving problem-
solving therapy, a type of cognitive-behavioral therapy (Gloaguen, Cottraux, Cucherat, & 
Blackburn, 1998). Lower levels of depression severity and rates of depression relapse 
may have lead IMPACT patients to be more engaged in their medical care (e.g., missing 
few health care visits; Bowser, Utz, Glick, & Harmon, 2010; DiMatteo, Lepper, & 
Croghan, 2000), which could also have led to a greater detection of new-onset diabetes. 
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4.4 Possible Explanations for Null Effect of Collaborative Depression Care on Diabetes 
Risk 
Three possible explanations for the null effect of collaborative depression care on 
diabetes risk are: (a) the lack of a sufficient effect on the mechanisms leading to the 
development of diabetes, (b) the older age of the IMPACT sample, and (c) ascertainment 
bias.  
Regarding the first possible explanation, it is conceivable that successful 
depression treatment alone may not have salutary effects on the hypothesized 
mechanisms underlying the prospective relationship between depression and diabetes 
(see Figure 1). Supporting this notion, Lin et al. (2006) found that depression treatment 
improved adherence and diabetes control in the IMPACT sample, but in a sample with 
existing diabetes. Moreover, other studies have found that enhanced depression care does 
not result in increased adherence to health behavior recommendations in cardiac patients 
(Huffman et al., 2011). For example, Kronish et al. (2012) reported that acute coronary 
syndrome patients who received depression treatment (psychotherapy and/or 
antidepressant medication) did not exhibit improved adherence to cardiovascular risk-
reducing behaviors, including taking aspirin daily, exercising regularly, and following a 
healthy diet. Similarly, other studies suggest that successful depression treatment does 
not dampen HPA axis hyperactivation (Appelhof et al., 2006; Kauffman et al., 2005). 
Finally, although the IMPACT group demonstrated a reduction in depressive symptoms, 
it is possible that the magnitude of this reduction was not sufficient to lead to 
improvement in the hypothesized mechanisms. Results of a number of past studies  
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suggest that remission of depression is necessary to improve diabetes markers (Kauffman 
et al., 2005; Okamura et al., 2000; Weber-Hamann et al., 2006; Weber-Hamann et al., 
2008). 
A second possible explanation for the null effect of collaborative depression care 
on diabetes risk is the older age of the sample. Because insulin resistance increases with 
age (Centers for Disease Control and Prevention, 2011), its severity in the IMPACT 
sample, despite the absence of diagnosed diabetes, was likely high. In addition, there was 
a high prevalence of diabetes risk factors (e.g., BMI) in the sample at baseline (see Table 
3). Together, the older age and, therefore, severity of insulin resistance of this cohort, in 
conjunction with its high baseline diabetes risk factors status, may have overridden any 
effect of depression treatment on diabetes incidence. 
A third possible explanation for the null results is ascertainment bias – i.e., the 
possibility of systematic distortion in the measurement of the true frequency of a 
phenomenon (in this case, diabetes incidence). Ascertainment bias is a concern because 
only RMRS and CMS data were used to identify new cases of diabetes. Thus, only those 
patients who had their diabetes detected and diagnosed were considered to be diabetes 
cases; patients with undiagnosed diabetes were not detected. As was discussed in the 
preceding section, IMPACT patients had greater contact with the health care system 
during the trial and may have greater contact during the follow-up period. Therefore, 
there were more opportunities for the IMPACT patients to have their diabetes detected 
and diagnosed. This lack of systematic assessment of the presence of new-onset diabetes 
for all randomized patients may have resulted in an underestimation of the true incidence 
of diabetes, especially in the usual care group. 
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4.5 Secondary Analysis of the Beating the Blues for Your Heart Pilot Trial 
To explore whether depression treatment may have a beneficial effect on markers 
of diabetes risk when a systematic assessment of the outcome is performed, existing data 
from a separate small randomized controlled trial was examined. In the Beating the Blues 
for Your Heart pilot trial (PI: Stewart; ClinicalTrials.gov link: NCT01605552), depressed 
patients with no known CVD were recruited from local primary care clinics. Participants 
were randomized to an 8-session, empirically supported, computerized cognitive-
behavioral intervention for depression known as Beating the Blues® or to usual care. 
After three months, Beating the Blues patients exhibited greater pre- to post-treatment 
decreases in SCL-20 scores than usual care patients (d = 1.33, p = .02). In a secondary 
analysis of the randomized participants without self-reported diabetes at baseline 
(Beating the Blues: n = 6, usual care: n = 12), fasting glucose values were examined as 
the outcome. Over the 3-month intervention period, Beating the Blues patients 
demonstrated decreases in fasting glucose levels (mean change = -3.52 mg/dL), whereas 
usual care patients exhibited increases (mean change = +3.15 mg/dL). Although change 
in fasting glucose levels from pre- to post-treatment did not reach statistical significance 
(post-treatment adjusted for pre-treatment level: p = .101), the effect size was in the 
moderate-to large range (d = 0.88).  
Several differences in study design between this pilot trial and the IMPACT trial 
should be noted. These differences are: (a) sample age: patients aged 40+ years versus 
60+ years, (b) type of intervention: computerized cognitive-behavioral intervention 
versus collaborative care intervention, (c) duration of intervention: 3 months versus 12 
months, (d) duration of follow-up: 3 months versus 9 years, and (e) outcome: change in 
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glucose levels (systematically assessed) versus incident diabetes (not systematically 
assessed). The younger age of the Beating the Blues patients is a key advantage because 
40-60 years is when type 2 diabetes onset typically occurs (Go et al, 2013). Additionally, 
the use of an outcome that was systematically assessed at the end of the intervention 
period is a key advantage, as it greatly minimizes the potential for ascertainment bias. 
Results of this secondary analysis (a) suggest that it would be premature to draw firm 
conclusions from the present analysis of the IMPACT data and (b) raise the possibility 
that treating depression among depressed, middle-aged adults without diabetes holds 
promise for lowering diabetes risk. 
 
4.6 Limitations 
As with all studies, the present study has limitations, including ascertainment bias, 
its post hoc nature, the lack of data for other diabetes risk factors, the primary definition 
of incident diabetes, and external validity. Ascertainment bias is discussed in the 
preceding section. The present study is post hoc in nature because the multisite IMPACT 
trial was not originally designed to test the study hypotheses, and consequently, 
randomization was not stratified by baseline diabetes status. While patients without 
diabetes were equally distributed across the treatment groups, no significant group 
differences in baseline characteristics were observed, and a strong theoretical rationale 
was present, only a prospective randomized controlled trial specifically designed to test 
the study hypotheses would allow for definitive conclusions to be drawn. Because the 
IMPACT study was not designed to assess diabetes outcomes, some diabetes risk factors 
were not assessed at baseline, such as physical inactivity and excessive alcohol use. Thus, 
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it is unknown if the treatment groups differed in these characteristics at baseline. The 
primary definition of incident diabetes was by no means definitive, and other potential 
definitions could have been used. This definition was chosen because it was likely to 
provide the best balance of sensitivity and specificity, although this could not be 
evaluated empirically. Of note, the prevalence rate of diabetes obtained using the primary 
definition is similar those found in other samples of older adults (Go et al., 2013). The 
external validity of the current findings is also a concern. Because the IMPACT 
participants were older and had high diabetes risk factor burden, the present findings 
might not generalize to healthier and middle-aged or younger adults. 
 
4.7 Future Directions and Recommendations 
Because the present results are not definitive due to the aforementioned 
methodological issues, further research is needed to determine whether depression 
treatment lowers diabetes risk. A potential next step for this area of research would be to 
conduct a moderately-sized, phase II trial involving depressed patients aged 40-60 years 
who are free of diabetes. This trial could use a continuous, intermediate diabetes 
endpoint, such as insulin resistance, as the primary outcome. There are several 
methodological features this trial should possess to enhance the validity of the findings. 
First, this trial should include a priori designation of hypotheses and outcomes, as well as 
power calculations to determine the sample size necessary to detect effects if they exist. 
Second, this trial should include a systematic assessment of diabetes outcomes to ensure 
that ascertainment bias is not an issue. Ideally, outcomes would be assessed immediately 
after the intervention period, as well as after a reasonable follow-up period. Third, this 
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trial should also collect long-term clinical data, such as new-onset diabetes. Because 
gains in clinical outcomes often lag behind gains in affective status (Rost, Nutting, Smith, 
Elliott, & Miriam Dickinson, 2002), assessing clinical outcomes immediately after the 
intervention period may miss group differences that emerge later. Fourth, this trial should 
deliver a depression intervention that results in depression remission for a high 
percentage of patients in the treatment arm. Several studies have reported that depression 
remission is necessary to improve diabetes-related outcomes (Lustman et al., 2006, 
2007a, 2008). Lastly, this ideal study should also detect the possible harmful effect of 
depression treatment on weight and, thus, diabetes risk markers by assessing these factors 
in a rigorous manner. In sum, a phase II trial that includes the methodological features 
described above would provide a stronger test of the hypotheses of the present study. 
If future well-designed and executed trials determine that depression treatment 
does not lower diabetes risk, then identifying other approaches for reducing the elevated 
diabetes risk of depressed patients need to be identified. One approach would be to treat 
the biological and/or behavioral mechanisms underlying the depression-diabetes 
association along with depression. The current cornerstones of diabetes prevention are 
non-pharmacological interventions that include physical activity and dietary components. 
In the Diabetes Prevention Program, an intensive lifestyle intervention was found to be 
effective in restoring normal glucose levels and reducing the incidence of diabetes in 
adults at high risk (Knowler et al., 2002). For depressed patient who are at risk for type 2 
diabetes, an integrated biopsychosocial treatment program that includes comprehensive 
depression care and a lifestyle intervention may help to reduce diabetes risk. One  
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intriguing hypothesis that a trial of an integrated intervention could test is whether the 
combination of depression and lifestyle interventions is superior to the lifestyle 
intervention alone in lowering diabetes risk. 
 
4.8 Conclusions 
Altogether, the results of this 9-year follow-up of the IMPACT trial suggest that 
effective depression treatment alone may not be necessary or sufficient to reduce diabetes 
incidence among depressed, older adults. These findings are inconsistent with 
preliminary findings of smaller intervention studies, including the secondary analysis of 
the Beating the Blues for Your Heart trial presented above. Possible explanations for the 
null findings of this study include the lack of a sufficient treatment effect on the 
mechanisms leading to the development of diabetes, the older age of the IMPACT 
sample, and ascertainment bias. Due to these methodological issues and the inconsistent 
findings across studies, it remains an open question as to whether depression treatment 
alone lower diabetes risk. Future prospective randomized controlled trials are needed to 
definitively test the present study's hypotheses. If these trials yield positive results, it 
would identify depression as a causal risk factor for diabetes and encourage providers 
toincorporate depression treatments in diabetes prevention efforts.
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Table 1. Indicators, Data Sources, and Frequencies for the Baseline Diabetes Variables (N=235) 
 
Baseline Variables Indicators Data Sources Frequency 
1. Diabetes 
Diagnoses 
 
a) ICD-9 Diabetes Codes:  
• "Hospital ICD-9 diagnosis" contains: 
• "Admitting ICD-9 diagnosis" contains:  
• "Primary care diagnosis" contains: 
• "Clinic billing diagnosis" contains: 
• 250.XX  
• Regenstrief Medical Records System 
• Medicare Inpatient Standard Analytic file 
• Medicare Outpatient Standard Analytic file 
• Medicare Carrier Standard Analytic File 
• Medicare Home Health Agency Standard 
Analytic File 
• Medicare Hospice Standard Analytic File 
• Medicare Skilled Nursing Standard 
Analytic File 
• Indiana Medicaid Claims 
 
94 (40%) 
 b) Diabetes Diagnosis Text Field Phrases: 
• V "diabetes mel non insulin dep" 
• V "diabetes mel insulin dep"  
• V "diabetes out of control"  
• V "diabetes uncontrolled 
 
• Regenstrief Medical Records System 40 (17.0%) 
2. Diabetes 
Complications 
 
 
 
 
 
 
 
 
 
Diabetes Complications Text Field Phrases: 
• V "diabetic ketoacidos" 
• V "diabetic neuropathy"  
• V "diabetic retinopathy" 
• V "diab hyperosm coma adult"  
• V "diab nephropathy adlt controlled" 
• V "diab nephropathy adlt uncontroll" 
• V "diab nephropathy juv controlled" 
• V "diab nephropathy juv uncontroll"  
• V "diabetic enteropathy"  
• V "diabetic foot ulcer" 
• V "diabetic lipodystrophy"  
• V "background diabetic retinopathy" 
• V "pre prolif diabetic retinopathy"  
• V "proliferatv diabetic retinopathy" 
• Regenstrief Medical Records System 22 (9.4%) 
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Table 1 continued. Indicators, Data Sources, and Frequencies for the Baseline Diabetes Variables (N=235) 
 
Baseline Variables Indicators Data Sources Frequency 
2. Diabetes 
Complications 
(contd.) 
 
• V "diabetic skin ulcer"   
3. Diabetes 
Laboratory 
Values 
 
a) Fasting Glucose Values: 
• "Glu Fasting" ≥ 126 
• "Gluc-GTT-75gm-Fast" ≥ 126 
 
• Regenstrief Medical Records System 58 (24.7%) 
 b) HbA1c Values: 
• "Glycosylated HGB tests" ≥ 8.5% 
• "HGB A1C-calculated" ≥ 8.5% 
 
• Regenstrief Medical Records System 65 (27.7%) 
4. Diabetes 
Medications 
 
a) Insulin Prescription: 
• "Insulins"  
• "Insulin Hum 70/30"  
• "Humulin 50/50"  
• "Insulin Lispro"  
• "Insulin Pen"  
• "Insulin SS Hum R"  
• "Insulin Drip" 
 
• Regenstrief Medical Records System 
• Medicare, Part D 
33 (14.0%) 
 b) Prescription for Oral Hypoglycemic Medications: 
• Glyburide 
• Glyburide Prestab 
• Glipizide 
• Glipizide Xl 
• Glimepiride 
• Gliquidone 
• Glyclopyramide 
• Gliclazide 
• Rosiglitazone  
• Pioglitazone  
• Regenstrief Medical Records System 
• Medicare, Part D 
26 (11.1%) 
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Table 1 continued. Indicators, Data Sources, and Frequencies for the Baseline Diabetes Variables (N=235) 
 
Baseline Variables Indicators Data Sources Frequency 
4. Diabetes   
Medications 
(contd.) 
b) Prescription for Oral Hypoglycemic Medications: 
• Troglitazone  
• Acarbose 
• Miglitol 
• Repaglinide 
• Nateglinide  
• Exenatide 
• Pramlintide 
• Liraglutide 
• Tolbutamide 
• Tolazamide 
• Chlorpropamide 
• Acetohexamide 
• Saxagliptin 
• Linagliptin 
• Vildagliptin 
• Alogliptin  
• Sitagliptin 
• Dapagliflozin 
• Canagliflozin 
• Regenstrief Medical Records System 
• Medicare, Part D 
26 (11.1%) 
5. Self-reported 
Diabetes 
Self-report Question Assessing Diabetes Status: 
• “Has a doctor or another health care worker 
diagnosed you with or treated you for high 
blood sugar or diabetes in the past 3 years?” 
 
• IMPACT baseline structured interview 
 
86 (36.6%) 
Note. N = 235. ICD-9 = International Classification of Diseases-9th Revision. HbA1c = Hemoglobin A1c 
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Table 2. Indicators, Data Sources, and Frequencies for the Incident Diabetes Variables (N=160) 
 
Outcome Variables Indicator Data Sources Frequency 
1. Diabetes 
Diagnoses 
 
a) ICD-9 Diabetes Codes:  
• "Hospital ICD-9 diagnosis" contains: 
• "Admitting ICD-9 diagnosis " contains:  
• "Primary care diagnosis " contains: 
• "Clinic billing diagnosis " contains: 
• 250.XX 
 
 
• Regenstrief Medical Records System  
• Medicare Inpatient Standard Analytic file 
• Medicare Outpatient Standard Analytic file 
• Medicare Carrier Standard Analytic File 
• Medicare Home Health Agency Standard 
Analytic File 
• Medicare Hospice Standard Analytic File 
• Medicare Skilled Nursing Standard Analytic 
File 
• Indiana Medicaid Claims 
 
46 (28.8%) 
 b) Diabetes Diagnosis Text Field Phrases: 
• V "diabetes mel non insulin dep" 
• V "diabetes mel insulin dep"  
• V "diabetes out of control"  
• V "diabetes uncontrolled" 
• Regenstrief Medical Records System 7 (4.4%) 
2. Diabetes 
Complications 
 
Diabetes Complications Text Field Phrases: 
• V "diabetic ketoacidos" 
• V "diabetic neuropathy"  
• V "diabetic retinopathy" 
• V "diab hyperosm coma adult"  
• V "diab nephropathy adlt controlled" 
• V "diab nephropathy adlt uncontroll" 
• V "diabetic enteropathy"  
• V "diabetic foot ulcer" 
• V "diabetic lipodystrophy"  
• V "background diabetic retinopathy" 
• V "pre prolif diabetic retinopathy"  
• V "proliferatv diabetic retinopathy" 
• V "diabetic skin ulcer" 
• Regenstrief Medical Records System 7 (4.4%) 
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Table 2 continued. Indicators, Data Sources, and Frequencies for the Incident Diabetes Variables (N=160) 
 
Outcome Variables Indicator Data Sources Frequency 
3. Diabetes 
Laboratory 
Values 
 
a) Fasting Glucose Values: 
• "Glu fasting" ≥ 126 
• "Gluc-GTT-75gm-fast" ≥ 126 
 
• Regenstrief Medical Records System 51 (31.9%) 
 b) HbA1c Values: 
• "Glycosylated HGB tests" ≥ 8.5% 
• "HGB A1C-calculated" ≥ 8.5% 
 
• Regenstrief Medical Records System 13 (8.1%) 
4. Diabetes 
Medications 
 
a) Insulin Prescription: 
• "Insulins"  
• "Insulin Hum 70/30"  
• "Humulin 50/50"  
• "Insulin Lispro"  
• "Insulin Pen"  
• "Insulin SS Hum R"  
• "Insulin Drip" 
 
• Regenstrief Medical Records System 
• Medicare, Part D 
6 (3.8%) 
 b) Prescription for Oral Hypoglycemic Medications: 
• Glyburide 
• Glyburide Prestab 
• Glipizide 
• Glipizide Xl 
• Glimepiride 
• Gliquidone 
• Glyclopyramide 
• Gliclazide 
• Rosiglitazone  
• Pioglitazone  
• Troglitazone  
• Acarbose 
• Miglitol 
• Repaglinide 
• Regenstrief Medical Records System 
• Medicare, Part D 
13 (8.1%) 
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Table 2 continued. Indicators, Data Sources, and Frequencies for the Incident Diabetes Variables (N=160) 
 
Outcome Variables Indicator Data Sources Frequency 
4.    Diabetes 
Medications 
(contd.) 
 
b) Prescription for Oral Hypoglycemic Medications: 
• Nateglinide  
• Exenatide 
• Pramlintide  
• Liraglutide 
• Tolbutamide 
• Tolazamide 
• Chlorpropamide 
• Acetohexamide 
• Saxagliptin 
• Linagliptin  
• Vildagliptin 
• Alogliptin  
• Sitagliptin 
• Dapagliflozin 
• Canagliflozin  
• Regenstrief Medical Records System 
• Medicare, Part D 
13 (8.1%) 
Note. N = 160. ICD-9 = International Classification of Diseases-9th Revision. HbA1c = Hemoglobin A1c 
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Table 3. Characteristics of Participants by Treatment Group 
 
Characteristic IMPACT   
(n = 80) 
Usual Care 
(n = 80) 
p value 
Baseline Demographic Factors 
Age, mean (SD) 66.9 (6.8) 67.6 (6.9) .514 
Male, % 20.0 26.3 .348 
African-American†, % 41.3 47.5 .426 
Height (inches), mean (SD) 64.6 (3.1) 65.1 (3.8) .363 
Weight (pounds), mean (SD) 184.2 (53.5) 175.7 (54.6) .320 
    
Baseline Diabetes Risk Factors 
Hypertension, % 72.5 72.5 1.000 
Smoker, % 31.3 40.0 .248 
Body-Mass Index (kg/m2), mean (SD) 31.1 (8.9) 29.1 (8.3) .137 
    
Baseline Depression Variables 
MDD Only, % 13.8 10.0 .463 
Dysthymia Only, % 32.5 37.5 .507 
MDD and Dysthymia, % 53.8 52.5 .874 
SCL-20 Score, mean (SD) (range: 0-4) 1.4 (0.5) 1.5 (0.5) .074 
Antidepressant Use in Past 3 Months, % 56.3 47.5 .268 
    
Depression Outcomes and Care Variables    
SCL-20 Change, mean (SD) (N = 152) -0.3 (0.7) 0.0 (0.7) .013 
Antidepressants during the trial, % 73.8 65.0 .230 
Psychotherapy during the trial, % 61.3 21.3 <.001 
Note. N = 160 except where indicated. Independent samples t tests were used to compare 
groups on age, body mass index, baseline SCL-20 score, and SCL-20 change. All other 
group comparisons were made using chi-square tests. IMPACT = Improving Mood-
Promoting Access to Collaborative Treatment. MDD = major depressive disorder. SCL-
20 = Symptom Checklist-20. 
†Because only 5 (3%) patients and 4 (2%) patients fell into the Hispanic and Other 
categories, respectively, a dichotomous race/ethnicity variable (0 = White, Hispanic, and 
Other; 1 = African American) was created
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Table 4. Event Composition of the Primary Definition of Incident Diabetes by Treatment Group 
 
Events Total Sample  (N = 160) 
IMPACT  
(n = 80)  
Usual Care  
(n = 80) 
Total Events 33 22 11 
Composition of Events    
ICD-9 Code and Positive Fasting Glucose 16 (49%) 11(50%) 5 (46%) 
ICD-9 Code and Positive HbA1c 10 (30%) 8 (36%) 2 (18%) 
ICD-9 Code and Diabetes Medication 7 (21%) 3 (14%) 4 (36%) 
Note. ICD-9 = International Classification of Diseases-9th Revision. IMPACT = Improving Mood-Promoting 
Access to Collaborative Treatment. HbA1c = Hemoglobin A1c 
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Table 5. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident Diabetes 
 
 
Diabetes Outcome            
Total 
Sample 
(N = 160) 
IMPACT 
(n = 80) 
Usual Care 
(n = 80) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
Primary Definition ǁ 33 (20.6%) 22 (27.5%) 11 (13.7%) 1.94 0.93-4.02 .076 
Demographics Adjusted †    1.94 0.93-4.05 .075 
Diabetes Risk Factors 
Adjusted ‡ 
   1.73 0.81-3.68 .157 
       
Secondary Definition § 67 (41.9%)    37 (46.2%) 30 (37.5%) 1.23 0.76-1.99 .399 
Demographics Adjusted †    1.20 0.74-1.96 .454 
Diabetes Risk Factors 
Adjusted ‡ 
   1.11 0.68-1.82 .669 
       
ICD-9 Code Only * 46 (28.8%) 26 (32.5%) 20 (25.0%) 1.24 0.69-2.23 .476 
Demographics Adjusted †    1.23 0.68-2.22 .499 
Diabetes Risk Factors 
Adjusted ‡ 
   1.09 0.59-2.00 .781 
       
Fasting Glucose Values Only Ϯ 51 (31.9%) 31 (38.7%) 20 (25.0%) 1.57 0.89-2.75 .117 
Demographics Adjusted †    1.53 0.87-2.69 .141 
Diabetes Risk Factors 
Adjusted ‡ 
   1.42 0.80-2.52 .231 
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Table 5 continued. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident 
Diabetes 
 
 
Diabetes Outcome            
Total 
Sample 
(N = 160) 
IMPACT 
(n = 80) 
Usual Care 
(n = 80) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
HbA1c Only ǂ 13 (8.1%) 9 (11.2%) 4 (5.0%) 2.15 0.66-7.00 .202 
Demographics Adjusted †    2.12 0.65-6.98 .215 
Diabetes Risk Factors 
Adjusted ‡ 
   1.65 0.47-5.75 .429 
       
Diabetes Medication Only ± 19 (11.9%) 11 (13.7%) 8 (10.0%) 1.33 0.53-3.31 .539 
Demographics Adjusted †    1.44 0.57-3.61 .443 
Diabetes Risk Factors 
Adjusted ‡ 
   1.25 0.48-3.28 .651 
Note. N = 160. HR = hazard ratio. CI = confidence interval. ICD-9 = International Classification of Diseases-9th Revision.         
IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. HbA1c = Hemoglobin A1c 
ǁ  Defined as [ICD-9 code AND (fasting glucose OR HbA1c OR diabetes medication)]. 
† Adjusted for age, sex, and race/ethnicity.  
‡ Adjusted for age, sex, race/ethnicity, hypertension, smoking status, and body mass index. Body mass index was an            
independent predictor of incident diabetes in the expected direction (HR = 1.08, 95% CI: 1.04-1.12, p < .001). 
§ Defined as (ICD-9 code OR fasting glucose OR HbA1c OR diabetes medication).  
* Defined as an ICD-9 code for diabetes.  
Ϯ Defined as a fasting glucose value ≥ 126mg/dL.  
ǂ  Defined as an HbA1c value ≥ 8.5%.  
± Defined as a prescription for diabetes medication (insulin or oral hypoglycemic medication).  
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Table 6. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident Diabetes – 
Broad Baseline Definition 
 
 
Diabetes Outcome            
Total 
Sample 
(N = 120) 
IMPACT 
(n = 60) 
Usual Care 
(n = 60) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
Primary Definition ǁ 16 (13.3%) 12 (20.0%) 4 (6.7%) 2.76 0.88-8.66 .083 
Demographics Adjusted †    3.27 1.03-10.35 .044 
Diabetes Risk Factors 
Adjusted ‡ 
   2.25 0.65-7.84 .201 
       
Secondary Definition § 40 (33.3%) 23 (38.3%) 17 (28.3%) 1.35 0.72-2.53 .348 
Demographics Adjusted †    1.38 0.73-2.60 .322 
Diabetes Risk Factors 
Adjusted ‡ 
   1.24 0.64-2.38 .521 
       
ICD-9 Code Only * 21 (17.5%) 14 (23.3) 7 (11.7%) 1.90 0.76-4.76 .171 
Demographics Adjusted †    2.07 0.82-5.25 .126 
Diabetes Risk Factors 
Adjusted ‡ 
   1.80 0.68-4.76 .237 
       
Fasting Glucose Values Only Ϯ 34 (28.3%) 20 (33.3%) 14 (23.3%) 1.36 0.86-2.69 .382 
Demographics Adjusted †    1.40 0.70-2.78 .341 
Diabetes Risk Factors 
Adjusted ‡ 
   1.17 0.57-2.37 .672 
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Table 6 continued. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident 
Diabetes – Broad Baseline Definition 
 
 
Diabetes Outcome            
Total 
Sample 
(N = 120) 
IMPACT 
(n = 60) 
Usual Care 
(n = 60) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
HbA1c Only ǂ 6 (5.0%) 6 (5.0%) 0 (0.0%) 60.7 0.08-
45482.82 
.224 
Demographics Adjusted †    --- --- --- 
Diabetes Risk Factors 
Adjusted ‡ 
   --- --- --- 
       
Diabetes Medication Only ± 7 (5.8%) 5 (8.3%) 2 (3.3%) 2.56 0.50-13.17 .262 
Demographics Adjusted †    4.79 0.85-27.00 .076 
Diabetes Risk Factors 
Adjusted ‡ 
   5.62 0.67-47.28 .112 
Note. N = 120. HR = hazard ratio. CI = confidence interval. ICD-9 = International Classification of Diseases-9th Revision.         
IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. HbA1c = Hemoglobin A1c 
ǁ Defined as [ICD-9 code AND (fasting glucose OR HbA1c OR diabetes medication)]. 
† Adjusted for age, sex, and race/ethnicity.  
‡ Adjusted for age, sex, race/ethnicity, hypertension, smoking status, and body mass index. Body mass index was an            
independent predictor of incident diabetes in the expected direction (HR = 1.08, 95% CI: 1.04-1.12, p < .001). 
§ Defined as (ICD-9 code OR fasting glucose OR HbA1c OR diabetes medication).  
* Defined as an ICD-9 code for diabetes.  
Ϯ Defined as a fasting glucose value ≥ 126mg/dL.  
ǂ Defined as an HbA1c value ≥ 8.5%.  
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Table 7. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident Diabetes - 
HbA1c ≥ 8.0% 
 
 
Diabetes Outcome            
Total 
Sample 
(N = 159) 
IMPACT 
(n = 79) 
Usual Care 
(n = 80) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
Primary Definition ǁ 33 (20.8%) 22 (27.8%) 11 (13.8%) 1.78 0.86-3.68 .118 
Demographics Adjusted †    1.84 0.88-3.86 .105 
Diabetes Risk Factors 
Adjusted ‡ 
   1.68 0.78-3.63 .186 
       
Secondary Definition § 66 (41.5%) 36 (45.6%) 30 (37.7%) 1.20 0.74-1.95 .458 
Demographics Adjusted †    1.18 0.72-1.92 .510 
Diabetes Risk Factors 
Adjusted ‡ 
   1.09 0.67-1.79 .721 
       
ICD-9 Code Only * 45 (28.3%) 20 (25.0%) 25 (31.6%) 1.19 0.66-2.16 .556 
Demographics Adjusted †    1.19 0.65-2.16 .568 
Diabetes Risk Factors 
Adjusted ‡ 
   1.07 0.58-1.97 .837 
       
Fasting Glucose Values Only Ϯ 51 (32.1%) 20 (25.0%) 31 (39.2%) 1.60 0.91-2.80 .102 
Demographics Adjusted †    1.56 0.89-2.75 .120 
Diabetes Risk Factors 
Adjusted ‡ 
   1.47 0.83-2.60 .190 
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Table 7 continued. Results of Cox Proportional Hazard Regression Models Examining Treatment Group as a Predictor of Incident 
Diabetes - HbA1c ≥ 8.0%  
 
 
Diabetes Outcome            
Total 
Sample 
(N = 160) 
IMPACT 
(n = 80) 
Usual Care 
(n = 80) 
Treatment Group 
(IMPACT vs. Usual Care) 
Events (%) HR 95% CI p value 
HbA1c Only ǂ 16 (10.1%) 10 (12.7%) 6 (7.5%) 1.62 0.59-4.44 .354 
Demographics Adjusted †    1.62 0.58-4.50 .353 
Diabetes Risk Factors 
Adjusted ‡ 
   1.49 0.51-4.36 .467 
       
Diabetes Medication Only ± 19 (11.9%) 11 (13.9%) 8 (10.0%) 1.35 0.54-3.36 .515 
Demographics Adjusted †    1.47 0.58-3.68 .416 
Diabetes Risk Factors 
Adjusted ‡ 
   1.27 0.49-3.33 .622 
Note. N = 159. HR = hazard ratio. CI = confidence interval. ICD-9 = International Classification of Diseases-9th Revision.         
IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. HbA1c = Hemoglobin A1c 
ǁ  Defined as [ICD-9 code AND (fasting glucose OR HbA1c OR diabetes medication)]. 
† Adjusted for age, sex, and race/ethnicity.  
‡ Adjusted for age, sex, race/ethnicity, hypertension, smoking status, and body mass index. Body mass index was an            
independent predictor of incident diabetes in the expected direction (HR = 1.08, 95% CI: 1.04-1.12, p < .001). 
§ Defined as (ICD-9 code OR fasting glucose OR HbA1c OR diabetes medication).  
* Defined as an ICD-9 code for diabetes.  
Ϯ Defined as a fasting glucose value ≥ 126mg/dL.  
ǂ  Defined as an HbA1c value ≥ 8.0%.  
± Defined as a prescription for diabetes medication (insulin or oral hypoglycemic medication).  
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Figure 1. Hypothesized mechanisms underlying the prospective relationship between depression and diabetes. 
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Figure 2. Flowchart of participants from the Indiana sites of the Improving Mood-
Promoting Access to Collaborative Treatment (IMPACT) randomized controlled trial.  
Baseline Diabetes Exclusion (n = 40) 
Randomized (n = 235) 
 
Analysis 
Allocation 
9-Year Follow-Up 
Enrollment 
Analyzed (n = 80) 
Allocated to Intervention (n = 120) 
Analyzed (n = 80) 
Lost to Follow-up (n = 0) 
Allocated to Usual Care (n = 115) 
Approached for Depression Screen 
(n = 3,675) 
Completed Eligibility Interview   
(n = 431) 
Excluded  (n = 196) 
• Negative Interview (n = 147) 
• Declined to Participate (n = 49) 
Excluded  (n = 3,244) 
• Refused Screen (n = 172) 
• Incomplete Screen (n = 5) 
• Negative Screen (n = 2,870) 
• Refused Eligibility Interview (n = 
Lost to Follow-up (n = 0) 
Baseline Diabetes Exclusion (n = 35) 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Change in depressive symptom severity (SCL-20) from pre-treatment to 12-
month post-treatment for the IMPACT group (n = 80) and the usual care group (n = 80). 
SCL-20 = Symptom Checklist-20.  
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Figure 4. Kaplan-Meier survival curves for time to incident diabetes (ICD-9 diabetes 
code and positive laboratory value or diabetes medication use) among depressed patients 
initially free of diabetes. IMPACT = Improving Mood-Promoting Access to 
Collaborative Treatment. 
p = .071 
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 IUPUI School of Science 
April 2012 Doctoral Fellowship ($1,500) 
Southern Regional Education Board, Institute on Teaching and 
Mentoring 
March 2013 Clinical Psychology Award for Citizenship ($100)  
 IUPUI Department of Psychology 
February 2013 Educational Enhancement Grant for Research Travel ($500)  
IUPUI Graduate Student Office  
January 2013 Young Scholar Award ($500) 
American Psychosomatic Society 2013, Miami, FL 
February 2012 Educational Enhancement Grant for Research Travel ($500) 
IUPUI Graduate Student Office  
 
112 
 
 
 
December 2011 Citation Abstract 
Society of Behavioral Medicine 2012, New Orleans, LA 
December 2011 Meritorious Student Abstract 
Society of Behavioral Medicine 2012, New Orleans, LA 
April 2011 Research Travel Award ($150)  
IUPUI Department of Psychology  
April 2011 Poster Award Finalist 
IUPUI Graduate Research Day 
2006 – 2009  Dean’s List 
College of the Arts and Sciences, Ohio State University 
PEER-REVIEWED PUBLICATIONS   
Khambaty, T., & Stewart, J. C. (2013). Associations of Depressive and Anxiety 
Disorders with Periodontal Disease Prevalence in Young Adults: Analysis of 
1999–2004 National Health and Nutrition Examination Survey (NHANES) Data. 
Annals of Behavioral Medicine, 1-5. 
Hickman, R. J., Khambaty, T., & Stewart, J. C. (2013). C-Reactive Protein is Elevated 
in Atypical but not Nonatypical Depression: Data from the National Health and 
Nutrition Examination Survey (NHANES) 1999–2004. Journal of Behavioral 
Medicine, 1-9. 
Khambaty, T., Stewart, J. C., Muldoon, M. F., & Kamarck, T. W. (2014). Depressive 
Symptom Clusters as Predictors of 6-Year Increases in Insulin Resistance: Data 
from the Pittsburgh Healthy Heart Project. Psychosomatic Medicine, 363-369. 
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Berntson, J., Stewart, K. R., Vrany, E., Khambaty, T., & Stewart, J. C. (2015). 
Depressive symptoms and self-reported adherence to medical recommendations to 
prevent cardiovascular disease: NHANES 2005–2010.Social Science & 
Medicine, 138, 74-81. 
Vrany, E., Berntson, J., Khambaty, T., & Stewart, J. C. (in press). Somatic, but not 
Nonsomatic, Symptoms of Depression are Associated with Insulin Resistance: 
National Health and Nutrition Examination Survey (NHANES) 2005-2010. 
Annals of Behavioral Medicine. 
MANUSCRUPTS UNDER REVIEW 
Khambaty, T., Callahan C. M., & Stewart, J. C. Depression Treatment and Diabetes 
Risk: A 9-Year Follow-up Study of the IMPACT Trial. 
Miles, S.R., Khambaty, T., Peterson, N., Naik, A.D, & Cully, J.A. Knowledge Isn’t 
Everything: The Role of Affect and Coping in Diabetes Care for Rural Adults 
with Uncontrolled Diabetes 
Stewart, J.C., Hawkins, M.A.W., Khambaty, T., Perkins, A.J., & Callahan, C.M. 
Depression and Anxiety Screens as Predictors of 8-Year Incidence of Myocardial 
Infarction and Stroke in Primary Care Patients 
White, J. R., Chang, C.H., So-Armah, K.A., Stewart, J.C., Gupta, S.K., Butt, A.A., 
Gibert, C.A., Rimland D., Rodriguez-Barradas, M.C., Leaf,  D.A., Bedimo, R.J., 
Gottdiener, J.S., Kop, W.J., Gottlieb, S.S., Budoff,  M.J., Khambaty, T., Tindle, 
H., Justice, A.C., and Freiberg, M.S. (2014). Depression and HIV Infection are 
Risk Factors for Incident Heart Failure among Veterans: Veterans Aging Cohort 
Study.  
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MANUSCRIPTS IN PREPARATION 
Khambaty, T., Stewart, J. C., Gupta, S. K., Chang, J., Bedimo R., Budoff, M., Butt, A., 
Crane, H., Gibert, C., Leaf, D., Rimland, D., Tindle, H., & Freiberg, M. S. 
Depressive Disorders Predict Incident Acute Myocardial Infarction in HIV+ 
Veterans: Veterans Aging Cohort Study. 
Khambaty, T., Callahan, C.M., Perkins, A.J., & Stewart, J. C. Depression and Anxiety 
Screens as Predictors of 9-Year Incidence of Diabetes. 
CONFERENCE PRESENTATIONS 
Oral Presentations at National Meetings: 
Khambaty, T., Callahan, C.M., Perkins, A.J., & Stewart, J. C. (2015, March). 
Depression and Anxiety Screens as Predictors of 9-Year Incidence of Diabetes. 
Paper  presented at the 73nd Annual Scientific Meeting of the American 
Psychosomatic Society, Savannah, GA. 
White, J. R., Chang, C.H., So-Armah, K.A., Stewart, J.C., Gupta, S.K., Butt, A.A., 
Gibert, C.A., Rimland D., Rodriguez-Barradas, M.C., Leaf  D.A.,  Bedimo, R.J., 
Gottdiener J.S., Kop W.J.,  Gottlieb S.S., Budoff  M.J., Khambaty T.; Tindle H., 
Justice A.C., and Freiberg M.S. (2014). Antidepressant Use and Incident Heart 
Failure among Veterans with and without HIV Infection and Major Depressive 
Disorder. Paper presented at 2015 American Heart Association Epidemiology & 
Prevention / Lifestyle and Cardiometabolic Health Scientific Sessions 
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Khambaty, T., & Stewart, J. C. (2014, March). Atypical Major Depression is more 
Strongly Associated with Diabetes Prevalence Three Years Later than 
Nonatypical Depression and Dysthymia: National Epidemiologic Survey on 
Alcohol and Related Conditions (NESARC). Paper presented at the 72nd Annual 
Scientific Meeting of the American Psychosomatic Society, San Francisco, CA. 
White, J. R., Chang, C.H., So-Armah, K.A., Stewart, J.C., Gupta, S.K., Butt, A.A., 
Gibert, C.A., Rimland D., Rodriguez-Barradas, M.C., Leaf  D.A.,  Bedimo, R.J., 
Gottdiener J.S., Kop W.J.,  Gottlieb S.S., Budoff  M.J., Khambaty T.; Tindle H., 
Justice A.C., and Freiberg M.S. (2014). Depression and HIV Infection are Risk 
Factors for Incident Heart Failure among Veterans: Veterans Aging Cohort 
Study. Paper presented at the 2014 Annual Meeting of the Conference on 
Retroviruses and Opportunistic Infections, Boston, MA. 
Khambaty, T., Stewart, J. C., Muldoon, M. F., & Kamarck, T. W. (2013, March). 
Somatic-Vegetative Symptoms of Depression Predict 6-Year Increases in Insulin 
Resistance: Data from the Pittsburgh Healthy Heart Project.  Paper presented at 
the 71st Annual meeting of the American Psychosomatic Society, Miami, FL. 
(Young Scholar Award) 
Vrany, E., Berntson, J., Khambaty, T., & Stewart, J. C. (2013, March). Somatic, but not 
Nonsomatic, Symptoms of Depression are Associated with Insulin Resistance: 
National Health and Nutrition Examination Survey (NHANES) 2005-2010.  
Paper presented at the 71st Annual meeting of the American Psychosomatic 
Society, Miami, FL.  
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Khambaty, T., & Stewart, J. C. (2012, April). Multiple Emotional Factors as Predictors 
of Cardiovascular Disease Incidence: Analysis of NHANES I Data. Paper 
presented at the 33rd Annual meeting of the Society of Behavioral Medicine, New 
Orleans, LA. (Citation Abstract)  
Poster Presentations at National Meetings: 
Khambaty, T., Callahan C. M., & Stewart, J. C. (2015, March). Depression Treatment 
and Diabetes Risk: A 9-Year Follow-up Study of the IMPACT Trial. Poster 
presented at the 73nd Annual Scientific Meeting of the American Psychosomatic 
Society, Savannah, GA. 
Khambaty, T., Stewart, J. C., Gupta, S. K., Chang, J., Butt, A., Gibert, C., Tindle, H., 
Crane, H., Bedimo R., & Freiberg, M. S. (2014, March). Depressive Disorders 
Predict Incident Acute Myocardial Infarction in HIV+ Veterans: Veterans Aging 
Cohort Study.  Poster presented at the 2014 Annual Meeting of the Conference on 
Retroviruses and Opportunistic Infections, Boston, MA. (Young Investigator 
Award) 
Stewart J. C., Gupta, S. K., Khambaty, T., Berntson, J., Considine, R. V., & Callahan, C. 
M. (2014, March). Effect of Computerized Depression Treatment on Endothelial 
Dysfunction: The Beating the Blues for Your Heart Pilot Trial. Poster presented 
at the 72nd Annual Scientific Meeting of the American Psychosomatic Society, 
San Francisco, CA 
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Stewart, J. C., Hickman, R. J., & Khambaty, T. (2013, March).  C-Reactive Protein is 
Elevated in Atypical but not Nonatypical Depression: National Health and 
Nutrition Examination Survey (NHANES) 1999-2004. Poster presented at the 71st 
Annual meeting of the American Psychosomatic Society, Miami, FL.  
Berntson, J., Stewart, K. R., Vrany, E., Khambaty, T., & Stewart, J. C. (2013, March). 
Depressive Symptoms are Associated with Poor Adherence to Some Lifestyle but 
not Medication Recommendations to Prevent Cardiovascular Disease: National 
Health and Nutrition Examination Survey (NHANES) 2005-2010. Poster 
presented at the 71st Annual meeting of the American Psychosomatic Society, 
Miami, FL.  
Khambaty, T., & Stewart, J. C. (2012, April). Multiple Emotional Factors and the 
Prevalence of Periodontal Disease: Analysis of NHANES I Data. Poster 
presented at the 33rd Annual meeting of the Society of Behavioral Medicine, New 
Orleans, LA. 
Khambaty, T., & Stewart, J. C. (2011, March). Associations between Depressive and 
Anxiety disorders and Periodontal Disease: Analysis of 1999-2004 NHANES 
data. Poster presented at the 69th Annual meeting of the American 
Psychosomatic Society, San Antonio, TX.   
INVITED LECTURES AND COLLOQUIA 
Khambaty, T. (2014, February). Depressive Disorders Predict Incident Acute 
Myocardial Infarction in HIV+ Veterans: Veterans Aging Cohort Study. One hour 
research conference presentation to the Indiana University School of Medicine 
Division of Infectious Diseases faculty and fellows, Indianapolis, IN. 
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Khambaty, T. (2013, March). Clinical Case Presentation on Cognitive Behavioral 
Therapy for Depression: Sara. A one hour clinical presentation at the IUPUI 
Department of Psychology Proseminar, attended by graduate students and faculty, 
Indianapolis, IN.  
Khambaty, T. (2012, October). Depression and Cardiovascular Disease (CVD): An 
Introduction. Guest lecture to an Abnormal Psychology undergraduate class, 
Indianapolis, IN. 
Khambaty, T. (2012, January). The Role of Emotional Factors in Periodontal Disease. 
A half-hour research presentation at the IUPUI Department of Psychology 
Proseminar, attended by graduate students and faculty, Indianapolis, IN. 
RESEARCH ACTIVITIES 
August 2014 - Healthy Outcomes for Patient Empowerment (HOPE) 
July 2015  Houston Center for Innovations in Quality, Effectiveness and 
Safety 
NCT01572389; November 2012-March 2016 
Principal Investigators: Aanand Naik, MD, Jeffrey Cully, PhD 
Veterans Health Administration, Health Services Research & 
Development  
Roles:    Manuscript preparation; Protocol therapist 
Study Objective:  Phase 3 multi-clinic, patient-level randomized controlled trial 
examining clinical effectiveness and preliminary implementation 
outcomes of a blended depression and diabetes behavioral health 
coaching intervention delivered by telephone 
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Duties:  Write and submit one first-author and one second-author 
manuscript based on baseline data; Deliver 9 telephone based 
intervention sessions over a six-month period; Sessions focus on 
physical and emotional health skills to address diabetes and 
depression based on principles of goal setting and action planning 
and evidence-based psychotherapy, including cognitive-behavioral 
therapy and motivational interviewing.  
January 2011- Targeting Systemic Inflammation to Concurrently Treat Late 
March 2014 Life Depression and  Reduce Coronary Artery Disease Risk  
R24 MH080827; January 2011-March 2014  
Principal Investigator: Jesse C. Stewart, PhD 
$465,718  
NIH/NIMH 
Role:    Project coordinator; Protocol therapist 
Study Objective:  Phase 2 randomized controlled trial evaluating whether 
pentoxifylline, a medication that interferes with the inflammatory 
cytokine cascade, is efficacious for concurrently treating late-life 
depression and endothelial dysfunction, an early marker of 
atherosclerotic cardiovascular disease.  
Duties:  Trained and supervised research assistants; Implemented an 
internet treatment for depression among primary care patients in a 
medical setting; Screened for and appropriately addressed 
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suicidality; Monitored and helped manage adverse events; Wrote 
and submitted IRB documents and amendments  
January 2011 -   Computer-Based Depression Treatment to Reduce Coronary 
June 2014 Artery Disease Risk Pilot Clinical Trial 
11CRP4880000; January 2011-July 2013  
Principal Investigator: Jesse C. Stewart, PhD 
$110,000  
American Heart Association 
Role:    Project coordinator; Protocol therapist 
Study Objective:  To evaluate whether an empirically supported, computer-based, 
cognitive behavioral intervention for depression - Beating the 
Blues® - delivered before the onset of cardiovascular disease, 
reduces coronary artery disease risk, indicated by brachial flow-
mediated dilation, a noninvasive measure of endothelial function.  
Duties:  Led project meetings with multi-disciplinary (doctors, nurses, 
ultrasonographers and the ResNet recruitment team) Indiana 
University and Wishard Hospital teams; Coordinated all study-
related activities; Trained and supervised research assistants; 
Implemented an internet treatment for depression among primary 
care patients in a medical setting; Wrote and submitted IRB 
documents; Corresponded with IRB personnel to ensure ethical 
execution of scientific goals; Conducted data analyses and 
reviewed conference abstract. 
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January 2013 - Dissertation Research 
June 2014 Department of Psychology, IUPUI 
Committee:   Christopher M. Callahan, MD 
Adam T. Hirsh, PhD 
Catherine E. Mosher, PhD 
Jesse C. Stewart, PhD 
Summary: Research indicates that depressive symptoms and disorders predict 
the onset and progression of type 2 diabetes. However, few clinical 
trials have evaluated the influence of pharmacological or 
psychological depression treatment on diabetes outcomes. 
Accordingly, I proposed a 9-year follow-up study of the Improving 
Mood-Promoting Access to Collaborative Treatment (IMPACT) 
trial to examine whether collaborative care for depression, 
including antidepressant medications and psychotherapy, reduces 
the likelihood of incident diabetes among otherwise healthy 
individuals (N=235). This is the first study to examine whether 
depression is a causal risk factor for incident type 2 diabetes. 
Findings were inconsistent with the notion that depression is a 
casual risk factor for diabetes and suggested that collaborative 
depression care alone is insufficient for reducing the excess 
diabetes risk of depressed, older adults.   
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January 2012 - Preliminary Examination Research 
December 2012 Department of Psychology, IUPUI 
Committee:   Adam T. Hirsh, PhD 
   Melissa A. Cyders, PhD, HSPP 
Jesse C. Stewart, PhD 
Summary: In this comprehensive literature review, I examined 78 studies that 
investigated the possible roles (i.e.,  Antecedent, Consequence, 
Epiphenomenon, or Moderator) that psychological distress, 
including negative emotional factors (e.g., depression, anxiety, and 
hostility/anger) or chronic stress (e.g., occupational, academic, 
marital, and financial stress), could have in the development, 
progression, and treatment of periodontal disease. This is the first 
review to (1) define these four potential roles, (2) critically 
evaluate both the direct empirical evidence and indirect evidence 
(i.e., plausibility) for or against these roles, and (3) develop a 
future research agenda for this area. In the review, I recommend 
that research in this area may benefit from collaborations between 
psychologists and dentists. 
August 2009 -  Master’s Thesis Research 
December 2011 Department of Psychology, IUPUI 
Committee:   Michelle P. Salyers, PhD 
Melissa A. Cyders, PhD, HSPP 
Jesse C. Stewart, PhD 
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Summary: Epidemiological studies suggest that depression may be an 
independent risk factor for cardiovascular disease (CVD). 
Although several possible mediators of this association have been 
proposed, the precise mechanisms are yet unknown. Accordingly, I 
examined periodontal disease as a novel mediator of the 
depression-CVD association, given its separate links with both 
depression and CVD. Data from the National Health and Nutrition 
Examination Survey (NHANES) I and its Epidemiologic Follow-
up Study (NHEFS) were analyzed. Participants were 3,346 
individuals aged 25-74 years free of CVD at baseline (53% female, 
16% non-white). The primary outcome was incident CVD (N=727, 
22%), defined as nonfatal or fatal coronary artery disease or 
cerebrovascular disease, identified during the follow-up period by 
interviews and death certificate records. Results suggested that (a) 
both periodontal disease and depressed mood are independent 
predictors of incident CVD and that (b) the effect of depressive 
symptoms on incident CVD is not mediated by periodontal disease.  
June 2007 -   Depression Research Laboratory  
May 2009  Department of Psychology, Ohio State University, Columbus, OH  
Role:    Honors Thesis Student; Research Assistant  
Duties:  Administered the Structural Clinical Interview for Depression 
(SCID); Oriented participants to study protocol and Electronic 
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Momentary Assessment devices; Collect heart rate variability data; 
Administered psychological assessments via Survey Monkey 
December 2007 - Honors Thesis 
May 2009  Department of Psychology, Ohio State University, Columbus, OH 
Committee:  Daniel R. Strunk, PhD 
   Jennifer Cheavens, PhD 
Summary:  Developed a research experiment to examine the association of 
diurnal mood variability with depressive symptoms, stress, and 
coping skills; Submitted IRB application for study approval; 
Developed research-related materials and questionnaires on Survey 
Monkey; Trained five undergraduate students in experimental 
procedures; Analyzed data using SAS software; Wrote and 
defended findings during a thesis committee meeting  
September 2006 -  Social Psychology Laboratory,  
May 2007 Department of Psychology, Ohio State University, Columbus, OH 
Role:    Research Assistant 
Duties: Helped conduct various experiments in the lab; Administered 
computer based questionnaires and conducted experimental 
protocols and debriefing; Entered data for analyses 
September 2005 - Behavioral Neuroscience Laboratory 
May 2006 Department of Psychology, Ohio State University, Columbus, OH 
Role:    Research Assistant 
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Duties: Helped conduct T-maze experiments on spatial memory utilizing a 
rat model of Alzheimer’s disease. 
RESEARCH WORKSHOPS 
August 2013  Meta-Analysis  
   (Three day workshop) 
Speaker:   Noel Card, PhD 
   Associate Professor, University of Arizona  
July 2013 Scientific Writing from the Reader's Perspective with Dr. 
George Gopen 
(Full day workshop) 
Speaker:   George Gopen, PhD, JD  
Professor of the Practice of Rhetoric 
Senior Lecturing Fellow, Duke University 
August 2012  Structural Equation Modeling  
  (Three day workshop) 
Speaker:   Gregory R. Hancock, PhD 
Professor and Chair, Measurement, Statistics and Evaluation 
Department of Human Development and Quantitative 
Methodology,  University of Maryland 
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TEACHING ACTIVITIES 
August 2010 -  Undergraduate Capstone Course in Applied Psychology (B433) 
December 2010 Department of Psychology, IUPUI 
Role:    Guest Lecturer 
Duties:  Presented four lectures on utilizing SPSS software for statistical 
analyses of undergraduate class research projects. 
August 2010 -  Graduate Psychological Assessment Course (664) 
December 2010 Department of Psychology, IUPUI 
Role:    Teaching Assistant 
Duties:  Instructed first year graduate students in the administration of the 
WAIS-IV and WISC-IV; Graded integrated reports. 
January 2010 -  Undergraduate Capstone Course in Social Psychology (B471) 
May 2010  Department of Psychology, IUPUI 
Role:    Teaching Assistant 
Responsibilities:  Presented lectures; Evaluated student performance on class 
assignments and research projects. 
August 2009 -  Undergraduate Capstone Course in Applied Psychology (B433) 
December 2009 Department of Psychology, IUPUI 
Position:   Teaching Assistant 
Responsibilities:  Co-led three lectures on SPSS statistical analysis software; 
Evaluated student performance on class assignments. 
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SERVICE AND LEADERSHIP 
March 2014 - Emerging Leader, Professional Education Committee  
Present   American Psychosomatic Society (APS) 
Role:   Emerging leader 
Duties: Attend monthly conference calls with Professional Education 
Committee and alternate-monthly calls with other Emerging 
Leaders Initiative group; Review educational materials (e.g., 
conference presentations) for the APS website. Aid in the 
development of pre-conference workshops; Work with Emerging 
Leaders on outreach and promotion of the professional education 
mission of APS; Complete alternate-monthly progress reports 
August 2012 -  Search Committee for two tenure-track faculty members  
January 2013  Depart of Psychology, IUPUI, Indianapolis, IN 
Role:    Student Representative  
Duties:  Gathered and organized application materials via spreadsheets; 
Corresponded with applicants on an as needed basis; Created 
schedules for interview visits; Created brochures and 
advertisements for job-talks; Provided general help to applicants 
during their interview day. 
August 2010 -  Psychology Graduate Student Organization (PGSO) 
May 2011  Department of Psychology, IUPUI, Indianapolis, IN 
Role:    Clinical Area Representative 
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Duties: Gathered ideas for improvement from clinical area graduate 
students and relayed to organization board; Developed innovative 
methods to implement ideas. 
PROFESSIONAL MEMBERSHIPS 
2010 – Present American Psychosomatic Society, Associate Member 
2011 – Present Indiana Psychological Society, Student Member 
2012 – 2013  Society of Behavioral Medicine, Student Member 
CLINICAL ACTIVITIES 
January 2013 -  Larue D. Carter Memorial Inpatient State Psychiatric Hospital 
May 2013  Indianapolis, IN  
Role:    Practicum Student (290 hours) 
Supervisors:   Kristine Chapleau, PhD, HSPP 
Timothy Lines, PhD, HSPP 
Duties:  Conducted short- and long-term therapy using techniques from 
metacognitive therapy, dialectical behavioral therapy, and 
cognitive behavioral therapy with adults with severe mental 
illnesses (e.g., schizophrenia, and bipolar disorder);  Led or co-led 
three therapy groups per week; Completed 7 psychosocial intake 
assessments at patient admission or annual review and offered 
diagnostic summaries; Individual therapy case-load of 4-6 patients 
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August 2012 -  Inpatient Consultation-Liaison Psychiatry Service 
December 2012 Indiana University Hospital, Department of Psychiatry,  
Indianapolis, IN 
Role:    Psychiatry Consultant (129 hours) 
Supervisor:   David Fingerhut, PhD, HSPP 
Duties:  Worked with an interdisciplinary team comprised of a psychiatrist, 
psychologist, and registered nurse; Conducted semi-structured 
interviews, and provided brief interventions with diverse patients 
(e.g., lower socioeconomic status clients on Medicare/Medicaid, 
self-pay clients, young and older adults) and presenting problems 
(depression, anxiety, panic disorder, psychosocial issues); Wrote 
concise evaluation notes in a timely manner; Communicated both 
within the Psychiatry team,  members of other medical teams, and 
nursing staff to inquire about patient progress and report 
consultation findings; Attended rounds with the Neurology team to 
gain an interdisciplinary perspective. 
January 2012 -  Adult Outpatient Psychiatry Clinic 
July 2012  Indiana University School of Medicine 
  Indianapolis, IN 
Role:    Practicum Student (239 hours) 
Supervisor:   Yelena Chernyak, PhD, HSPP 
Duties:  Conducted initial intake assessments for patients; Provided 
individual therapy to patients presenting with a range of issues and 
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psychiatric disorders (e.g., mood and anxiety disorders, bipolar 
disorder, insomnia, PTSD, academic difficulties and marital 
distress); Primary therapeutic modalities included cognitive-
behavioral therapy and acceptance and commitment therapy; 
Developed evidence based treatment plans; Utilized established 
symptom inventories to monitor patient progress. 
August 2011 -  Community Bariatric Associates  
January 2012  Community South Hospital 
Indianapolis, IN 
Role:    Practicum Student (259 hours) 
Supervisor:   Theresa Rader, PsyD, HSPP 
Duties:  Administered, scored, and interpreted an evidence-based 
assessment battery for patients seeking bariatric surgery; Assessed 
readiness for surgery and psychological functioning, including the 
presence of mood, anxiety, and personality disorders, coping skills, 
and brief cognitive functioning; Provided feedback and 
recommendations to patients orally and in written reports; Co-led 
8-week bariatric educational groups focusing on diet, exercise, and 
cognitive-behavioral therapy and acceptance and commitment 
therapy techniques; Wrote 13 integrative reports. 
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January 2011 -  St. Vincent Joshua Max Simon Primary Care Center 
July 2011  St. Vincent Family and Internal Medicine 
   Indianapolis, IN 
Role:    Student Behavioral Health Consultant (349 hours)  
Supervisor:   Thomas Barbera, PhD, HSPP 
Duties:  Work with an integrated care team of residents, attendings, nurses, 
psychiatrists, and social workers to provide brief individual 
therapy on issues of chronic pain, weight management, nicotine 
dependence, insomnia, drug and alcohol dependence, and 
mood/anxiety disorders; Primary therapeutic modality was 
cognitive-behavioral therapy; Conducted motivational interviewing 
for weight management and nicotine dependence; Provided 
relaxation training for anxiety; Utilized the electronic medical 
records system to review charts and write progress notes; Attended 
didactic seminars. 
August 2010 -  Post-Traumatic Stress Disorder Clinical Team (PCT) 
January 2011 Psychiatry Ambulatory Care Clinic (PACC) 
Richard L. Roudebush VA Medical Center  
Indianapolis, IN 
Role:    Practicum Student (202 hours) 
Supervisor:   David Tarr, PhD, HSPP 
Duties:  Conducted individual therapy with male and female veterans 
presenting with PTSD, substance use disorders, mood/anxiety 
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disorders, and comorbid medical issues; Primary therapeutic 
modalities were cognitive-behavioral therapy and prolonged 
exposure; Developed recovery plans; Led or co-led cognitive-
behavioral therapy group for depression, Sleep/Anger group, and 
peer support group; Attended staff meetings; Utilized CPRS 
electronic medical record system to write progress notes. 
CLINICAL PEER SUPERVISION 
January 2012 -  Seminar in Teaching Psychology (I-595 graduate course) 
May 2012  Department of Psychology, IUPUI 
Role:    Clinical Peer Supervisor to Rebecca N. Adams 
Supervisor:   John Guare, PhD, HSPP  
Duties:  Provided 1 hour of peer supervision two times per month to a 
second year Clinical Psychology PhD student during her first 
practicum placement.  
August 2012 -   Seminar in Teaching Psychology (I-595 graduate course) 
December 2012 Department of Psychology, IUPUI 
Role:    Clinical Peer Supervisor to Kenny Karyadi 
Supervisor:   John Guare, PhD, HSPP  
Duties:  Provided 1 hour of peer supervision two times per month to a 
second year Clinical Psychology PhD student during his first 
practicum placement.  
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ASSESSMENTS ADMINISTERED 
Diagnostic Assessments:Alcohol Use Disorder Test (AUDIT); Beck Anxiety Inventory 
(BAI); Beck Depression Inventory (BDI); Beck Depression Inventory-II (BDI-II); Blood 
Pressure Questionnaire; Brief Pain Inventory (BPI); Buss–Perry Aggression 
Questionnaire (BPAQ); Burn’s EASY Diagnostic Survey; Drug Abuse Screening Test 
(DAST); Eating Attitudes Test (EAT-26); Generalized Anxiety Disorder 7-item scale 
(GAD-7); Geriatric Depression Scale (GDS); Headache Impact Test-6 item (HIT6); 
International Physical Activity Questionnaire (IPAQ);Mood Disorder Questionnaire 
(MDQ); Morisky Medication Adherence Questionnaire (MMAQ); Outcome Rating 
Scale; Patient Health Questionnaire-9 (PHQ-9); Positive and Negative Affect Schedule 
(PANAS); Pittsburgh Sleep Quality Index (PSQI); Structured Clinical Interview for 
DSM-IV Axis I Disorders, Clinician Version (SCID-I-CV); Symptom Checklist – 20 
(SCL-20); Tobacco Use Questionnaire; Weight and Lifestyle Inventory (WALI); Zung 
Self-report Anxiety Scale  
Intelligence and Achievement Assessments: Wechsler Adult Intelligence Scale (WAIS-
IV); Wechsler Intelligence Scale for Children (WISC-IV); Wide Range Achievement 
Test – IV (WRAT-IV); Woodcock Johnson-III 
Neuropsychological Assessments: Boston Naming Test (BNT); ; California Verbal 
Learning Test- Second edition (CVLT-II); Mini International Neuropsychiatric Interview 
(MINI) ; Mini-Mental Status Examination (MMSE); Paced Auditory Serial Addition 
Task (PASAT); Phonemic Fluency (FAS); PTSD CheckList (PCL); Repeatable Battery 
for the Assessment of Neuropsychological Status; Rey Auditory Verbal Learning Test; 
Satisfaction with Life Scale; Semantic Fluency (Animals); Stroop Color and Word Test 
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(STROOP); Trail Making Test (TMT); Test of Memory and Malingering (TOMM); 
Wisconsin Card Sorting Test (WCST); Word Memory Test (WMT) 
Personality Assessments: Millon Behavioral Medicine Diagnostic (MBMD); Millon 
Clinical Multiaxial Inventory (MCMI); Minnesota Multiphasic Personality Inventory-
Second Edition (MMPI-2); Minnesota Multiphasic personality Inventory-Second Edition 
Restructured Form (MMPI-2-RF); Rorschach Test; Thematic Apperception Test (TAT) 
WORKSHOPS AND SPECIALTY TRAINING 
October 2014 The Many Faces of Diversity: Increasing Cultural Competence 
When Working With Veterans And Employees With 
Disabilities (Full day workshop) 
Speakers:  Linda R. Mona, PhD 
Clinical Psychologist, Director of Psychology Postdoctoral 
Training, Long Beach VA Medical Center 
Kevin Curtis, JD, LLM, VA Regional Council 
September 2014 Minnesota Multiphasic Personality Inventory-2-Restructured 
Form (Full day workshop) 
Speaker:   Paul A. Arbisi, PhD  
   Department of Psychology,  
Minneapolis VA Medical Center, University of Minnesota 
Spring 2014  Biofeedback  (Half day workshop) 
Speaker:  Eric L. Scott, PhD 
Assistant Professor of Clinical Psychology in Clinical Psychiatry 
Riley Hospital for Children 
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August 2010 -  Metasupervision, Department of Psychology, IUPUI 
May 2013   (2-hour meeting monthly) 
Supervisor:   John C. Guare, PhD, HSPP 
Purpose:  Supervision meetings with students enrolled in practicum and a 
licensed practicum supervisor for the purpose of discussion 
progress in our respective practicum placements; Received 
supervision and feedback on audio recordings of therapy sessions 
August 2009 -  Proseminar in Clinical Psychology, Department of Psychology, 
May 2013  IUPUI (1-hour weekly departmental meeting) 
Purpose:  Professional development course covering advanced clinical and 
research related topics via talks and presentations by invited 
speakers, and department faculty and students; Relevant topics 
included: diversity, internship and post-doctoral training and 
preparation, grant-writing, consulting, ethics, and supervision. 
October 2013  Consultation Seminar (Half day workshop) 
Speaker:   Susan Hickman, PhD 
Associate Professor, School of Nursing, IUPUI 
August 2013   Infusing Diversity into Teaching (Half day workshop) 
Speaker:   Leslie Ashburn-Nardo, PhD 
Associate Professor of Psychology, IUPUI 
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April 2013  Self-Hypnosis Training for Chronic Pain Management 
  (Half day workshop) 
Speaker:  Mark P. Jensen, PhD  
Associate Professor of Rehabilitation Science 
University of Washington 
January 2013  Consultation Liaison Supervision Training workshop 
  (Half day workshop) 
Speaker:   Angie Rollins, PhD 
Research Scientist, Research Director 
Assertive Community Treatment (ACT) Center of Indiana 
October 2011  Clinical Supervision Training (Full day workshop) 
Speaker:   Julie Lash, PhD 
Director, Counseling and Psychological Services, UPUI 
October 2011  Consultation: The Compass Model (Full day workshop) 
Speaker:  Lisa Ruble, PhD  
Associate Professor, Educational, School, and Counseling 
Psychology, University of Kentucky 
May 2011  Group Schema Therapy for Borderline Personality Disorder  
(Full day workshop) 
Speaker:   Dr. Joan Farrell, PhD, and Ida Shaw, MSW  
Training Directors of the Center of BPD Treatment and Research, 
Department of Psychiatry 
Indiana University School of Medicine, Larue Carter Hospital 
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March 2010 Evidence-based Practice: What Psychologists Need to Know 
and Why (Full day workshop) 
Speaker:   Barbara Walker, PhD 
Professor, Department of Psychological and Brain Sciences 
   Indiana University, Bloomington 
